{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
    },
    "document_metadata": {
      "authors": "Trusha Adeshara",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosi",
      "version": "1.0.0"
    },
    "namespace_pattern": {},
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns",
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/501ceccdc9a27d97edbdc48a89ebe8e1dd3626e9/export/conso-names.belns",
      "DOID": "https://raw.githubusercontent.com/pharmacome/terminology/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns",
      "EFO": "https://raw.githubusercontent.com/pharmacome/conso/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns",
      "HP": "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/hp-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/conso/f02c6ad4a4791a8ed45448513b9de8c8f1b00c87/external/mesh-names.belns"
    },
    "path": "ms/garg2015.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Multiple sclerosis is an autoimmune inﬂammatory disorder of CNS of unknown etiology, characterized by demyelination and variable degrees of axonal loss.",
      "key": "74a2d138df26422c90fdf9171b75984f",
      "line": 78,
      "relation": "isA",
      "source": 98,
      "target": 94
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Multiple sclerosis is an autoimmune inﬂammatory disorder of CNS of unknown etiology, characterized by demyelination and variable degrees of axonal loss.",
      "key": "cc495337954311234e20312b8c00d95f",
      "line": 79,
      "relation": "increases",
      "source": 98,
      "target": 140
    },
    {
      "annotations": {
        "Anatomy": {
          "cerebrospinal fluid": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "CSF inﬂammatory markers are present in up to 85% patients with MS (Link and Huang 2006); IgG index is less sensitive and speciﬁc than oligoclonal bands Awad et al. 2010).",
      "key": "0f382c07fd6ec969f7b9ce1097d90170",
      "line": 288,
      "relation": "increases",
      "source": 98,
      "target": 140
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Multiple sclerosis is an autoimmune inﬂammatory disorder of CNS of unknown etiology, characterized by demyelination and variable degrees of axonal loss.",
      "key": "84f7b7082f8848f1414136fc194434c6",
      "line": 80,
      "relation": "increases",
      "source": 98,
      "target": 115
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Multiple sclerosis is an autoimmune inﬂammatory disorder of CNS of unknown etiology, characterized by demyelination and variable degrees of axonal loss.",
      "key": "389bd6d1693294bb4865b87e56f7e678",
      "line": 81,
      "relation": "increases",
      "source": 98,
      "target": 114
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Although demyelination is the hallmark of MS pathology, early axonal injury and axonal loss also occur and may drive disability progression (Trapp et al. 1998).",
      "key": "1cbe914b79a6360ffa3645bcfea43991",
      "line": 215,
      "relation": "increases",
      "source": 98,
      "target": 114
    },
    {
      "annotations": {
        "Confidence": {
          "Low": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " Linkage analysis studies have revealed several gene loci as risk factors, with the major histocompatibility complex (MHC) HLA DR15/DQ6 allele being the strongest one (Barcellos et al. 2003; Sawcer et al. 2011). More recently, alleles of interleukin-2 receptor alpha gene (IL2RA) and interleukin-7 receptor alpha gene (IL7RA) have also been identiﬁed as inheritable risk factors (Haﬂer et al. 2007; Sawcer et al. 2011).",
      "key": "2031979d3e46b4b95c962ccb12299b70",
      "line": 86,
      "relation": "positiveCorrelation",
      "source": 98,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "Low": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " Linkage analysis studies have revealed several gene loci as risk factors, with the major histocompatibility complex (MHC) HLA DR15/DQ6 allele being the strongest one (Barcellos et al. 2003; Sawcer et al. 2011). More recently, alleles of interleukin-2 receptor alpha gene (IL2RA) and interleukin-7 receptor alpha gene (IL7RA) have also been identiﬁed as inheritable risk factors (Haﬂer et al. 2007; Sawcer et al. 2011).",
      "key": "3eba21f1fb8db588fd3bc931de96effa",
      "line": 87,
      "relation": "positiveCorrelation",
      "source": 98,
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "Low": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " Linkage analysis studies have revealed several gene loci as risk factors, with the major histocompatibility complex (MHC) HLA DR15/DQ6 allele being the strongest one (Barcellos et al. 2003; Sawcer et al. 2011). More recently, alleles of interleukin-2 receptor alpha gene (IL2RA) and interleukin-7 receptor alpha gene (IL7RA) have also been identiﬁed as inheritable risk factors (Haﬂer et al. 2007; Sawcer et al. 2011).",
      "key": "db47a76187d27dbeb078a4f7e983bfa7",
      "line": 88,
      "relation": "positiveCorrelation",
      "source": 98,
      "target": 70
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Among environmental factors, Epstein-Barr virus (EBV) infection and vitamin D deﬁciency have been extensively studied and strongly linked to MS risk (Ascherio and Munger 2007a,b)",
      "key": "2ef463bf30bb9773bd74b483f036ead5",
      "line": 93,
      "relation": "positiveCorrelation",
      "source": 98,
      "target": 133
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Among environmental factors, Epstein-Barr virus (EBV) infection and vitamin D deﬁciency have been extensively studied and strongly linked to MS risk (Ascherio and Munger 2007a,b)",
      "key": "cc51f224c773445334a3a2df19d662b7",
      "line": 94,
      "relation": "positiveCorrelation",
      "source": 98,
      "target": 135
    },
    {
      "annotations": {
        "Anatomy": {
          "central nervous system": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The immunopathogenesis of MS is thought to involve a breach of self-tolerance toward myelin and other CNS antigens resulting in persistent peripheral activation of autoreactive T cells (Haﬂer et al. 2005; Selter and Hemmer 2013).",
      "key": "7fdf1823d363db352ef0effc08e6d8a7",
      "line": 150,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 98,
      "target": 20
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The contribution of B cells to MS pathogenesis (possibly through autoantibody secretion and antigen presentation to T cells) has recently been recognized and is supported by observed pathologic heterogeneity of MS lesions, the presence of meningeal inﬂammation and B-cell follicle-like structures adjacent to subpial cortical lesions, and the success of B-cell-based immunotherapies (O’Connor et al. 2001; Batoulis et al. 2010; Naismith et al. 2010).",
      "key": "668f9aa1e9383132b759e619103cb65c",
      "line": 208,
      "relation": "association",
      "source": 98,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Although demyelination is the hallmark of MS pathology, early axonal injury and axonal loss also occur and may drive disability progression (Trapp et al. 1998).",
      "key": "3a300b21c89a2161187145a81504613b",
      "line": 216,
      "relation": "increases",
      "source": 98,
      "target": 132
    },
    {
      "annotations": {
        "Anatomy": {
          "cerebral cortex": true
        },
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Cortical lesions seen in early MS are usually highly inﬂammatory and correlate with cognitive impairment (Geurts and Barkhof 2008; Lucchinetti et al. 2011).",
      "key": "7cfa02e3de2998fec8afd8327b1bce49",
      "line": 264,
      "relation": "increases",
      "source": 98,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The clinical symptoms and signs of MS are variable and may result from involvement of sensory, motor, visual, and brainstem pathways.",
      "key": "1fed2777e836b5ff3008e838c18b57d2",
      "line": 272,
      "relation": "association",
      "source": 98,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The clinical symptoms and signs of MS are variable and may result from involvement of sensory, motor, visual, and brainstem pathways.",
      "key": "6462e1f61df4005eb138076addff35a1",
      "line": 273,
      "relation": "association",
      "source": 98,
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The clinical symptoms and signs of MS are variable and may result from involvement of sensory, motor, visual, and brainstem pathways.",
      "key": "5160f5c3b9734f9f1a58ae5ceb2cfcf0",
      "line": 274,
      "relation": "association",
      "source": 98,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The management of MS includes treatment with immunomodulatory agents that help alter the course of the disease, symptomatic management focusing on relieving speciﬁc symptoms such as fatigue, spasticity, bladder dysfunction, and pain (not discussed in this review).",
      "key": "f245fb680cda819e6d502ba3095f5aec",
      "line": 294,
      "relation": "increases",
      "source": 98,
      "target": 124
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The management of MS includes treatment with immunomodulatory agents that help alter the course of the disease, symptomatic management focusing on relieving speciﬁc symptoms such as fatigue, spasticity, bladder dysfunction, and pain (not discussed in this review).",
      "key": "f3af6d7b9e052fc58f4aebd2685e12a2",
      "line": 295,
      "relation": "increases",
      "source": 98,
      "target": 130
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The management of MS includes treatment with immunomodulatory agents that help alter the course of the disease, symptomatic management focusing on relieving speciﬁc symptoms such as fatigue, spasticity, bladder dysfunction, and pain (not discussed in this review).",
      "key": "9cedfc4436c511935a53bd3fcfdf14b0",
      "line": 296,
      "relation": "increases",
      "source": 98,
      "target": 118
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The management of MS includes treatment with immunomodulatory agents that help alter the course of the disease, symptomatic management focusing on relieving speciﬁc symptoms such as fatigue, spasticity, bladder dysfunction, and pain (not discussed in this review).",
      "key": "686f77cc9d2edd04d6c368fc4fc97309",
      "line": 297,
      "relation": "increases",
      "source": 98,
      "target": 100
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Although demyelination is the hallmark of MS pathology, early axonal injury and axonal loss also occur and may drive disability progression (Trapp et al. 1998).",
      "key": "2c57d9771a2448e7a1560e8c7838a9f9",
      "line": 214,
      "relation": "biomarkerFor",
      "source": 115,
      "target": 98
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The MS plaques or lesions are focal areas of demyelination associated with variable inﬂammation and axonal loss that predominantly affect the white matter of the brain, spinal cord, and optic nerves but can also involve the cerebral cortex including subpial regions (Sobel and Moore 2008; Popescu and Lucchinetti 2012).",
      "key": "2e164cc6085e9f2c8666400ee42f0fdb",
      "line": 249,
      "relation": "increases",
      "source": 115,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "Low": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " Linkage analysis studies have revealed several gene loci as risk factors, with the major histocompatibility complex (MHC) HLA DR15/DQ6 allele being the strongest one (Barcellos et al. 2003; Sawcer et al. 2011). More recently, alleles of interleukin-2 receptor alpha gene (IL2RA) and interleukin-7 receptor alpha gene (IL7RA) have also been identiﬁed as inheritable risk factors (Haﬂer et al. 2007; Sawcer et al. 2011).",
      "key": "c802594de59a738d6d4a9b45a1a0a320",
      "line": 86,
      "relation": "positiveCorrelation",
      "source": 71,
      "target": 98
    },
    {
      "annotations": {
        "Confidence": {
          "Low": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " Linkage analysis studies have revealed several gene loci as risk factors, with the major histocompatibility complex (MHC) HLA DR15/DQ6 allele being the strongest one (Barcellos et al. 2003; Sawcer et al. 2011). More recently, alleles of interleukin-2 receptor alpha gene (IL2RA) and interleukin-7 receptor alpha gene (IL7RA) have also been identiﬁed as inheritable risk factors (Haﬂer et al. 2007; Sawcer et al. 2011).",
      "key": "abab992bd97542dee3fec6b69f7cc842",
      "line": 87,
      "relation": "positiveCorrelation",
      "source": 69,
      "target": 98
    },
    {
      "annotations": {
        "Confidence": {
          "Low": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " Linkage analysis studies have revealed several gene loci as risk factors, with the major histocompatibility complex (MHC) HLA DR15/DQ6 allele being the strongest one (Barcellos et al. 2003; Sawcer et al. 2011). More recently, alleles of interleukin-2 receptor alpha gene (IL2RA) and interleukin-7 receptor alpha gene (IL7RA) have also been identiﬁed as inheritable risk factors (Haﬂer et al. 2007; Sawcer et al. 2011).",
      "key": "4bbb3cc0eab0de223c3036d5fb291bf7",
      "line": 88,
      "relation": "positiveCorrelation",
      "source": 70,
      "target": 98
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Among environmental factors, Epstein-Barr virus (EBV) infection and vitamin D deﬁciency have been extensively studied and strongly linked to MS risk (Ascherio and Munger 2007a,b)",
      "key": "35273eecf338f10c0c86d4de5b9cee00",
      "line": 93,
      "relation": "positiveCorrelation",
      "source": 133,
      "target": 98
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Among environmental factors, Epstein-Barr virus (EBV) infection and vitamin D deﬁciency have been extensively studied and strongly linked to MS risk (Ascherio and Munger 2007a,b)",
      "key": "883bd81fc036789146cda7da9edb3b1f",
      "line": 94,
      "relation": "positiveCorrelation",
      "source": 135,
      "target": 98
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Studies have suggested that  higher levels of vitamin D have a possible protective role in certain susceptible patient populations (Munger et al. 2004, 2006).",
      "key": "c53cc0bd9727c3b5133782a958fe96aa",
      "line": 100,
      "relation": "decreases",
      "source": 8,
      "target": 98
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The role of dietary factors appears to be complex and related to the inﬂuence of multiple dietary components including vitamin A and D, salt, omega-3-unsaturated fatty acid, and polyphenol on immune regulation.",
      "key": "14c77d47eba2a06520b6bdceedb43cd8",
      "line": 122,
      "relation": "regulates",
      "source": 8,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The “hygiene hypothesis,” supported by many epidemiological observations, suggests that improved sanitation and reduced childhood infections in developed countries may account for the increased rates of autoimmune diseases (T-helper 1 mediated) and allergy (T-helper 2 mediated) (Conradi et al. 2011).",
      "key": "05ac851840f049924adab62b3b32a736",
      "line": 106,
      "relation": "increases",
      "source": 33,
      "subject": {
        "modifier": "Activity"
      },
      "target": 131
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The evidence based on animal studies suggests that CD4+ T-helper 1 (TH1) cells which release proinﬂammatory cytokines such as interferon-gamma, interleukin-2 (IL-2), and tumor necrosis factor-a (TNF-a) are the key players in mediating inﬂammation in MS with some role for the novel CD4+ T-helper-17 (TH17) cell subset which secretes IL-17 (O’Connor et al. 2001; Selter and Hemmer 2013).",
      "key": "ab7658194cffd17ed918a44393dd9cc2",
      "line": 184,
      "relation": "increases",
      "source": 33,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The evidence based on animal studies suggests that CD4+ T-helper 1 (TH1) cells which release proinﬂammatory cytokines such as interferon-gamma, interleukin-2 (IL-2), and tumor necrosis factor-a (TNF-a) are the key players in mediating inﬂammation in MS with some role for the novel CD4+ T-helper-17 (TH17) cell subset which secretes IL-17 (O’Connor et al. 2001; Selter and Hemmer 2013).",
      "key": "193a310e720f195ebc955d62085aadff",
      "line": 185,
      "relation": "increases",
      "source": 33,
      "target": 85
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The evidence based on animal studies suggests that CD4+ T-helper 1 (TH1) cells which release proinﬂammatory cytokines such as interferon-gamma, interleukin-2 (IL-2), and tumor necrosis factor-a (TNF-a) are the key players in mediating inﬂammation in MS with some role for the novel CD4+ T-helper-17 (TH17) cell subset which secretes IL-17 (O’Connor et al. 2001; Selter and Hemmer 2013).",
      "key": "e953ddde43fa21907015620f3984c703",
      "line": 186,
      "relation": "increases",
      "source": 33,
      "target": 89
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The evidence based on animal studies suggests that CD4+ T-helper 1 (TH1) cells which release proinﬂammatory cytokines such as interferon-gamma, interleukin-2 (IL-2), and tumor necrosis factor-a (TNF-a) are the key players in mediating inﬂammation in MS with some role for the novel CD4+ T-helper-17 (TH17) cell subset which secretes IL-17 (O’Connor et al. 2001; Selter and Hemmer 2013).",
      "key": "e63f07e37252f4fc942a7c77b651d0b2",
      "line": 189,
      "relation": "association",
      "source": 33,
      "target": 34
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The “hygiene hypothesis,” supported by many epidemiological observations, suggests that improved sanitation and reduced childhood infections in developed countries may account for the increased rates of autoimmune diseases (T-helper 1 mediated) and allergy (T-helper 2 mediated) (Conradi et al. 2011).",
      "key": "6672d9cb085f6120c41c5dc0c55e7b84",
      "line": 107,
      "relation": "increases",
      "source": 43,
      "target": 131
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The “hygiene hypothesis,” supported by many epidemiological observations, suggests that improved sanitation and reduced childhood infections in developed countries may account for the increased rates of autoimmune diseases (T-helper 1 mediated) and allergy (T-helper 2 mediated) (Conradi et al. 2011).",
      "key": "06883611e793157aa8074c187b79e973",
      "line": 109,
      "relation": "increases",
      "source": 43,
      "target": 121
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The “hygiene hypothesis,” supported by many epidemiological observations, suggests that improved sanitation and reduced childhood infections in developed countries may account for the increased rates of autoimmune diseases (T-helper 1 mediated) and allergy (T-helper 2 mediated) (Conradi et al. 2011).",
      "key": "2451e0b500c61aaed728d33128981ecc",
      "line": 108,
      "relation": "increases",
      "source": 35,
      "subject": {
        "modifier": "Activity"
      },
      "target": 121
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The CD4+ T-helper 2 (TH2) cells, which secret interleukins 4, 5, and 10 are believed to have a counter regulatory role limiting the TH1-cell-mediated injury (Tzartos et al. 2008).",
      "key": "07591691c642986041c8a28de2a52656",
      "line": 195,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 35,
      "target": 78
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The CD4+ T-helper 2 (TH2) cells, which secret interleukins 4, 5, and 10 are believed to have a counter regulatory role limiting the TH1-cell-mediated injury (Tzartos et al. 2008).",
      "key": "65945add1c109e75193c416b44f366c0",
      "line": 196,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 35,
      "target": 79
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The CD4+ T-helper 2 (TH2) cells, which secret interleukins 4, 5, and 10 are believed to have a counter regulatory role limiting the TH1-cell-mediated injury (Tzartos et al. 2008).",
      "key": "b8c209d3c33558d4a2664b7a09212724",
      "line": 197,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 35,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The CD4+ T-helper 2 (TH2) cells, which secret interleukins 4, 5, and 10 are believed to have a counter regulatory role limiting the TH1-cell-mediated injury (Tzartos et al. 2008).",
      "key": "58a912551325bcdf6c4aa2fb6c8c7084",
      "line": 198,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 35,
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The “hygiene hypothesis,” supported by many epidemiological observations, suggests that improved sanitation and reduced childhood infections in developed countries may account for the increased rates of autoimmune diseases (T-helper 1 mediated) and allergy (T-helper 2 mediated) (Conradi et al. 2011).",
      "key": "b97d9003287cc102d28b7fb4a5c9e39e",
      "line": 110,
      "relation": "decreases",
      "source": 139,
      "target": 131
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The “hygiene hypothesis,” supported by many epidemiological observations, suggests that improved sanitation and reduced childhood infections in developed countries may account for the increased rates of autoimmune diseases (T-helper 1 mediated) and allergy (T-helper 2 mediated) (Conradi et al. 2011).",
      "key": "6ff9b4be78c46e02a8dfc646ba63879a",
      "line": 111,
      "relation": "decreases",
      "source": 139,
      "target": 121
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The odds ratio for developing MS is approximately 1.5 for smokers compared with nonsmokers (Wingerchuk 2012; Fragoso 2014).",
      "key": "fb3b3f6aa1eccab2984625ec54c30002",
      "line": 116,
      "relation": "increases",
      "source": 141,
      "target": 98
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The role of dietary factors appears to be complex and related to the inﬂuence of multiple dietary components including vitamin A and D, salt, omega-3-unsaturated fatty acid, and polyphenol on immune regulation.",
      "key": "22e7f8fc9feb9efe5a73ea32c669d987",
      "line": 121,
      "relation": "regulates",
      "source": 7,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The role of dietary factors appears to be complex and related to the inﬂuence of multiple dietary components including vitamin A and D, salt, omega-3-unsaturated fatty acid, and polyphenol on immune regulation.",
      "key": "8058e3b65bb9ff05ffd79e08ae5a51a4",
      "line": 123,
      "relation": "regulates",
      "source": 16,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "10095": true,
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Some recent reports have suggested that salt modulates the differentiation of human and mouse Th17 cells (Kleinewietfeld et al. 2013; Wu et al. 2013). A more aggressive course of experimental autoimmune encephalomyelitis (EAE) was observed in mice fed a high sodium diet. In a small observational study, higher sodium intake was associated with increased clinical and radiological disease activity in patients with MS (Farez et al. 2015).",
      "key": "96e0afba916a68b1fbb8580df17a5049",
      "line": 131,
      "relation": "regulates",
      "source": 16,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The role of dietary factors appears to be complex and related to the inﬂuence of multiple dietary components including vitamin A and D, salt, omega-3-unsaturated fatty acid, and polyphenol on immune regulation.",
      "key": "1277df49e33f2e9d99aa6ce83f4bf77c",
      "line": 124,
      "relation": "regulates",
      "source": 5,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The role of dietary factors appears to be complex and related to the inﬂuence of multiple dietary components including vitamin A and D, salt, omega-3-unsaturated fatty acid, and polyphenol on immune regulation.",
      "key": "02c9f56799e743669261a49e1a21fd4f",
      "line": 125,
      "relation": "regulates",
      "source": 15,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "10095": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Some recent reports have suggested that salt modulates the differentiation of human and mouse Th17 cells (Kleinewietfeld et al. 2013; Wu et al. 2013). A more aggressive course of experimental autoimmune encephalomyelitis (EAE) was observed in mice fed a high sodium diet. In a small observational study, higher sodium intake was associated with increased clinical and radiological disease activity in patients with MS (Farez et al. 2015).",
      "key": "6706834a1afcbc792a02a23ad624a3c4",
      "line": 134,
      "relation": "increases",
      "source": 6,
      "target": 111
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Some recent reports have suggested that salt modulates the differentiation of human and mouse Th17 cells (Kleinewietfeld et al. 2013; Wu et al. 2013). A more aggressive course of experimental autoimmune encephalomyelitis (EAE) was observed in mice fed a high sodium diet. In a small observational study, higher sodium intake was associated with increased clinical and radiological disease activity in patients with MS (Farez et al. 2015).",
      "key": "a184ea7052589c37ff04e133ee64e46a",
      "line": 136,
      "relation": "increases",
      "source": 6,
      "target": 98
    },
    {
      "annotations": {
        "Anatomy": {
          "central nervous system": true
        },
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The pathogenesis of MS involves immune attack against CNS antigens mediated through activated CD4+ myelin reactive T cells with a possible contribution by B cells.",
      "key": "cf3b08f9a6d386698dcd41c44a4453cf",
      "line": 143,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 26,
      "subject": {
        "modifier": "Activity"
      },
      "target": 20
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "fbe1a90975e4301087f7fcc83951eec5",
      "line": 221,
      "relation": "increases",
      "source": 26,
      "target": 115
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "0ffd7546770540425e6a0d69b4450188",
      "line": 222,
      "relation": "increases",
      "source": 26,
      "target": 132
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "e008e2756a9ce3ee3771c3f73844a308",
      "line": 223,
      "relation": "increases",
      "source": 26,
      "target": 54
    },
    {
      "key": "4671b06afe47a179754527db29d6afdf",
      "relation": "partOf",
      "source": 26,
      "target": 22
    },
    {
      "annotations": {
        "Anatomy": {
          "central nervous system": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The immunopathogenesis of MS is thought to involve a breach of self-tolerance toward myelin and other CNS antigens resulting in persistent peripheral activation of autoreactive T cells (Haﬂer et al. 2005; Selter and Hemmer 2013).",
      "key": "a6e2ea46b5ff95a417fc32dc2db6d4cd",
      "line": 151,
      "relation": "increases",
      "source": 20,
      "subject": {
        "modifier": "Degradation"
      },
      "target": 59
    },
    {
      "key": "c879bf107f5013e2471b425a786b847c",
      "relation": "partOf",
      "source": 20,
      "target": 64
    },
    {
      "annotations": {
        "Anatomy": {
          "central nervous system": true
        },
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The pathogenesis of MS involves immune attack against CNS antigens mediated through activated CD4+ myelin reactive T cells with a possible contribution by B cells.",
      "key": "c7fc018e31226a851fce640d60089932",
      "line": 144,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 24,
      "subject": {
        "modifier": "Activity"
      },
      "target": 20
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The contribution of B cells to MS pathogenesis (possibly through autoantibody secretion and antigen presentation to T cells) has recently been recognized and is supported by observed pathologic heterogeneity of MS lesions, the presence of meningeal inﬂammation and B-cell follicle-like structures adjacent to subpial cortical lesions, and the success of B-cell-based immunotherapies (O’Connor et al. 2001; Batoulis et al. 2010; Naismith et al. 2010).",
      "key": "cd2d949195ea34c8807b00cf8e918545",
      "line": 208,
      "relation": "association",
      "source": 24,
      "target": 98
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The contribution of B cells to MS pathogenesis (possibly through autoantibody secretion and antigen presentation to T cells) has recently been recognized and is supported by observed pathologic heterogeneity of MS lesions, the presence of meningeal inﬂammation and B-cell follicle-like structures adjacent to subpial cortical lesions, and the success of B-cell-based immunotherapies (O’Connor et al. 2001; Batoulis et al. 2010; Naismith et al. 2010).",
      "key": "2939f6ee76755aacd0df7f8645d10044",
      "line": 209,
      "relation": "increases",
      "source": 24,
      "target": 140
    },
    {
      "key": "5aeec1fc476bf19681b7669adce43f9c",
      "relation": "partOf",
      "source": 24,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The immunopathogenesis of MS is thought to involve a breach of self-tolerance toward myelin and other CNS antigens resulting in persistent peripheral activation of autoreactive T cells (Haﬂer et al. 2005; Selter and Hemmer 2013).",
      "key": "497597483226636e227000842ce2091d",
      "line": 153,
      "relation": "increases",
      "source": 59,
      "target": 137
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The immunopathogenesis of MS is thought to involve a breach of self-tolerance toward myelin and other CNS antigens resulting in persistent peripheral activation of autoreactive T cells (Haﬂer et al. 2005; Selter and Hemmer 2013).",
      "key": "b1fa7a9011f99b3c78209b23ec6b2826",
      "line": 154,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 59,
      "target": 32
    },
    {
      "key": "d2367e29001903c4177d28484cadfd6a",
      "relation": "partOf",
      "source": 32,
      "target": 64
    },
    {
      "key": "c822e1035d28ac0c6ff05b8028c3e7a4",
      "relation": "partOf",
      "source": 32,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The infection could cause bystander activation of T cells or result in release of autoantigens due to cellular damage, which can then lead to activation of T cells by cross reactivity between an endogenous protein (e.g., myelin basic protein) and the pathogenic exogenous protein (viral or bacterial antigen), a process known as molecular mimicry (Fujinami and Oldstone 1985; Wucherpfennig and Strominger 1995; Aichele et al. 1996; Gran et al. 1999; O’Connor et al. 2001).",
      "key": "0f2554f96647a0296160ce92b8c6efeb",
      "line": 160,
      "relation": "increases",
      "source": 117,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The infection could cause bystander activation of T cells or result in release of autoantigens due to cellular damage, which can then lead to activation of T cells by cross reactivity between an endogenous protein (e.g., myelin basic protein) and the pathogenic exogenous protein (viral or bacterial antigen), a process known as molecular mimicry (Fujinami and Oldstone 1985; Wucherpfennig and Strominger 1995; Aichele et al. 1996; Gran et al. 1999; O’Connor et al. 2001).",
      "key": "5d166ec2790f4ae5c5593e992e86d342",
      "line": 161,
      "relation": "increases",
      "source": 117,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The infection could cause bystander activation of T cells or result in release of autoantigens due to cellular damage, which can then lead to activation of T cells by cross reactivity between an endogenous protein (e.g., myelin basic protein) and the pathogenic exogenous protein (viral or bacterial antigen), a process known as molecular mimicry (Fujinami and Oldstone 1985; Wucherpfennig and Strominger 1995; Aichele et al. 1996; Gran et al. 1999; O’Connor et al. 2001).",
      "key": "f3888b2d69b8974806332d9222911c13",
      "line": 162,
      "relation": "increases",
      "source": 58,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The infection could cause bystander activation of T cells or result in release of autoantigens due to cellular damage, which can then lead to activation of T cells by cross reactivity between an endogenous protein (e.g., myelin basic protein) and the pathogenic exogenous protein (viral or bacterial antigen), a process known as molecular mimicry (Fujinami and Oldstone 1985; Wucherpfennig and Strominger 1995; Aichele et al. 1996; Gran et al. 1999; O’Connor et al. 2001).",
      "key": "d55eb7658643f86842659b16ef4a2c67",
      "line": 163,
      "relation": "increases",
      "source": 58,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The transmigration process involves interaction between very late antigen-4 (VLA-4) present on T lymphocytes and the vascular cell adhesion molecule-1 (VCAM-1) expressed on capillary endothelial cells; this process is facilitated by expression and upregulation of various adhesion molecules, chemokines, and matrix metalloproteinases (MMPs) (Yong 2004; Gold and Wolinsky 2011).",
      "key": "e1db3d0b5785a3b382d29471ef1a96f9",
      "line": 168,
      "relation": "increases",
      "source": 67,
      "target": 60
    },
    {
      "key": "49477ebdb167f5606cb9a1dd31c8ff6c",
      "relation": "partOf",
      "source": 86,
      "target": 67
    },
    {
      "key": "b369603ca9f1eb2c09a8575343170a38",
      "relation": "partOf",
      "source": 86,
      "target": 66
    },
    {
      "key": "5c1b0c58b81ca6baf15a80f6e14bed4a",
      "relation": "partOf",
      "source": 91,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The transmigration process involves interaction between very late antigen-4 (VLA-4) present on T lymphocytes and the vascular cell adhesion molecule-1 (VCAM-1) expressed on capillary endothelial cells; this process is facilitated by expression and upregulation of various adhesion molecules, chemokines, and matrix metalloproteinases (MMPs) (Yong 2004; Gold and Wolinsky 2011).",
      "key": "5076d6dc06addb511586548db37a5a34",
      "line": 169,
      "relation": "increases",
      "source": 28,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The transmigration process involves interaction between very late antigen-4 (VLA-4) present on T lymphocytes and the vascular cell adhesion molecule-1 (VCAM-1) expressed on capillary endothelial cells; this process is facilitated by expression and upregulation of various adhesion molecules, chemokines, and matrix metalloproteinases (MMPs) (Yong 2004; Gold and Wolinsky 2011).",
      "key": "af7919f7dd225180e491d6958646d95d",
      "line": 170,
      "relation": "increases",
      "source": 38,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The transmigration process involves interaction between very late antigen-4 (VLA-4) present on T lymphocytes and the vascular cell adhesion molecule-1 (VCAM-1) expressed on capillary endothelial cells; this process is facilitated by expression and upregulation of various adhesion molecules, chemokines, and matrix metalloproteinases (MMPs) (Yong 2004; Gold and Wolinsky 2011).",
      "key": "9688a7a5a5bcfb5b4a49f7879a3174e7",
      "line": 171,
      "relation": "increases",
      "source": 90,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "4d4b80ff72bee058f8e7715435e67465",
      "line": 242,
      "relation": "increases",
      "source": 90,
      "target": 115
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "9460d19660fd92bad2bc394f607f4ac2",
      "line": 243,
      "relation": "increases",
      "source": 90,
      "target": 132
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "da85b294a95b9a097d889e6625b26360",
      "line": 244,
      "relation": "increases",
      "source": 90,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Activation of resident CNS glial cells (such as microglia) results in persistent inﬂammation even in absence of further inﬁltration of exogenous inﬂammatory cells (O’Connor et al. 2001).",
      "key": "081c1f7af6aa27c89a5bdf3ec97f2370",
      "line": 176,
      "relation": "increases",
      "source": 40,
      "subject": {
        "modifier": "Activity"
      },
      "target": 140
    },
    {
      "key": "b55af76b38f561f0bd09dc7a69bf5072",
      "relation": "partOf",
      "source": 40,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The evidence based on animal studies suggests that CD4+ T-helper 1 (TH1) cells which release proinﬂammatory cytokines such as interferon-gamma, interleukin-2 (IL-2), and tumor necrosis factor-a (TNF-a) are the key players in mediating inﬂammation in MS with some role for the novel CD4+ T-helper-17 (TH17) cell subset which secretes IL-17 (O’Connor et al. 2001; Selter and Hemmer 2013).",
      "key": "4dc8b4b509993a196737e41ea452c237",
      "line": 187,
      "relation": "regulates",
      "source": 77,
      "target": 140
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The evidence based on animal studies suggests that CD4+ T-helper 1 (TH1) cells which release proinﬂammatory cytokines such as interferon-gamma, interleukin-2 (IL-2), and tumor necrosis factor-a (TNF-a) are the key players in mediating inﬂammation in MS with some role for the novel CD4+ T-helper-17 (TH17) cell subset which secretes IL-17 (O’Connor et al. 2001; Selter and Hemmer 2013).",
      "key": "8b0ea5b65b018a22a95f08ecdb7610bd",
      "line": 188,
      "relation": "regulates",
      "source": 85,
      "target": 140
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "39cf4102d56dc61bea81868f5ff6b737",
      "line": 236,
      "relation": "increases",
      "source": 85,
      "target": 115
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "357b91a581402b9e373567947f630f9e",
      "line": 237,
      "relation": "increases",
      "source": 85,
      "target": 132
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "ed6788235eaeaf48c5303825ecf61208",
      "line": 238,
      "relation": "increases",
      "source": 85,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The evidence based on animal studies suggests that CD4+ T-helper 1 (TH1) cells which release proinﬂammatory cytokines such as interferon-gamma, interleukin-2 (IL-2), and tumor necrosis factor-a (TNF-a) are the key players in mediating inﬂammation in MS with some role for the novel CD4+ T-helper-17 (TH17) cell subset which secretes IL-17 (O’Connor et al. 2001; Selter and Hemmer 2013).",
      "key": "d1f58b44c3c16bd5ba3d54f41b9a6fea",
      "line": 189,
      "relation": "association",
      "source": 34,
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The evidence based on animal studies suggests that CD4+ T-helper 1 (TH1) cells which release proinﬂammatory cytokines such as interferon-gamma, interleukin-2 (IL-2), and tumor necrosis factor-a (TNF-a) are the key players in mediating inﬂammation in MS with some role for the novel CD4+ T-helper-17 (TH17) cell subset which secretes IL-17 (O’Connor et al. 2001; Selter and Hemmer 2013).",
      "key": "771fc1ccb0490654ea9ea04747a1cd18",
      "line": 190,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 34,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "CD8+ T cells are believed to be involved as well and can induce axonal pathology by direct injury to MHC I/antigen expressing cells such as neurons and oligodendrocytes (Batoulis et al. 2010).",
      "key": "cddfb4d44b3bf5b390b130c3e7ef6991",
      "line": 203,
      "relation": "increases",
      "source": 27,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "f239fe0ea5b95dea97148a9c97f18edc",
      "line": 224,
      "relation": "increases",
      "source": 27,
      "target": 115
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "2726a39dc25dd40882dd5c8daea3ea8f",
      "line": 225,
      "relation": "increases",
      "source": 27,
      "target": 132
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "364df692209604833b18e4ce900a17b0",
      "line": 226,
      "relation": "increases",
      "source": 27,
      "target": 54
    },
    {
      "key": "77917c47b240f76eaf850628e377f64a",
      "relation": "partOf",
      "source": 27,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "818b39fa64dad5b55faa2f7669f42e0b",
      "line": 227,
      "relation": "increases",
      "source": 50,
      "target": 115
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "bcd027ce0c55ccb4ef136c5b3f71ccb3",
      "line": 228,
      "relation": "increases",
      "source": 50,
      "target": 132
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "20dd29c7b68a39b9ec077af988ffb44d",
      "line": 229,
      "relation": "increases",
      "source": 50,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "f7c92a6ec7b93873aef99a29f67e7049",
      "line": 230,
      "relation": "increases",
      "source": 49,
      "target": 115
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "57daf487e7dbe5374d8ff542d27c391f",
      "line": 231,
      "relation": "increases",
      "source": 49,
      "target": 132
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "2acb1e82d1b8297fc402614719800462",
      "line": 232,
      "relation": "increases",
      "source": 49,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "df3961572fc17144c8c36b8a3115317b",
      "line": 233,
      "relation": "increases",
      "source": 76,
      "target": 115
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "ae9cd65e4b9d3bc1eb2af003eeb66ab4",
      "line": 234,
      "relation": "increases",
      "source": 76,
      "target": 132
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "d4ad46ac662742cc8207e8b68017f122",
      "line": 235,
      "relation": "increases",
      "source": 76,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "73b1d17bc1bb4dc766d57a8de86595bc",
      "line": 239,
      "relation": "increases",
      "source": 4,
      "target": 115
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "d9f96f22ad03f048daf204b639d6c07f",
      "line": 240,
      "relation": "increases",
      "source": 4,
      "target": 132
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": " The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/ macrophages, and/or antibody and complement as well as the indirect effects of proinﬂammatory cytokines such as IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti et al. 2000; Hemmer et al. 2002; Gold and Wolinsky 2011).",
      "key": "d17e7c6aa0a39a202999724ea27bc25b",
      "line": 241,
      "relation": "increases",
      "source": 4,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The MS plaques or lesions are focal areas of demyelination associated with variable inﬂammation and axonal loss that predominantly affect the white matter of the brain, spinal cord, and optic nerves but can also involve the cerebral cortex including subpial regions (Sobel and Moore 2008; Popescu and Lucchinetti 2012).",
      "key": "1fa43e0ae68b64e94cca91cf08a41315",
      "line": 250,
      "relation": "increases",
      "source": 22,
      "target": 140
    },
    {
      "annotations": {
        "Anatomy": {
          "brain white matter": true,
          "cerebral cortex": true,
          "root of optic nerve": true,
          "spinal cord": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The MS plaques or lesions are focal areas of demyelination associated with variable inﬂammation and axonal loss that predominantly affect the white matter of the brain, spinal cord, and optic nerves but can also involve the cerebral cortex including subpial regions (Sobel and Moore 2008; Popescu and Lucchinetti 2012).",
      "key": "9f0998d811b68dc160a393aeda6b83d8",
      "line": 252,
      "relation": "increases",
      "source": 22,
      "target": 114
    },
    {
      "key": "4b706cfcab39eefe2a1cba4c1381975a",
      "relation": "partOf",
      "source": 31,
      "target": 22
    },
    {
      "annotations": {
        "Anatomy": {
          "cerebral cortex": true
        },
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Cortical lesions seen in early MS are usually highly inﬂammatory and correlate with cognitive impairment (Geurts and Barkhof 2008; Lucchinetti et al. 2011).",
      "key": "1afbcb4e047e13cff7c7debe375cc718",
      "line": 265,
      "relation": "increases",
      "source": 21,
      "target": 140
    },
    {
      "annotations": {
        "Anatomy": {
          "cerebral cortex": true
        },
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Cortical lesions seen in early MS are usually highly inﬂammatory and correlate with cognitive impairment (Geurts and Barkhof 2008; Lucchinetti et al. 2011).",
      "key": "b9eadf9ab66306503f09e0f5eb2fef93",
      "line": 266,
      "relation": "decreases",
      "source": 21,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The clinical symptoms and signs of MS are variable and may result from involvement of sensory, motor, visual, and brainstem pathways.",
      "key": "0dd7c541e0c9e0d16814300fca862aad",
      "line": 272,
      "relation": "association",
      "source": 55,
      "target": 98
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The clinical symptoms and signs of MS are variable and may result from involvement of sensory, motor, visual, and brainstem pathways.",
      "key": "7327b63355cd5019761f140ad70116da",
      "line": 273,
      "relation": "association",
      "source": 52,
      "target": 98
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The clinical symptoms and signs of MS are variable and may result from involvement of sensory, motor, visual, and brainstem pathways.",
      "key": "f58cb35382fcbc2e97ae6d843b5b7cda",
      "line": 274,
      "relation": "association",
      "source": 56,
      "target": 98
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The ﬁrst clinical event in these patients, termed clinically isolated syndrome (CIS), can be optic neuritis, incomplete myelitis, or brainstem syndrome (Miller et al. 2005).",
      "key": "92920a38a570443ecc9b173cb3de39df",
      "line": 280,
      "relation": "increases",
      "source": 102,
      "target": 99
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The ﬁrst clinical event in these patients, termed clinically isolated syndrome (CIS), can be optic neuritis, incomplete myelitis, or brainstem syndrome (Miller et al. 2005).",
      "key": "2f7cb42cdcee5fc1fff6a6e8dc9fdba7",
      "line": 281,
      "relation": "increases",
      "source": 102,
      "target": 109
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The ﬁrst clinical event in these patients, termed clinically isolated syndrome (CIS), can be optic neuritis, incomplete myelitis, or brainstem syndrome (Miller et al. 2005).",
      "key": "6880771629782ce29e2b042f9513be75",
      "line": 282,
      "relation": "increases",
      "source": 102,
      "target": 113
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Corticosteroids (methylprednisolone) and adrenocorticotropic hormone (ACTH) have anti-inﬂammatory and immunomodulatory effects and are typically used to treat acute relapse to hasten the recovery (Berkovich 2013).",
      "key": "45ee63c00a6840970293f0abe40439d8",
      "line": 302,
      "relation": "decreases",
      "source": 9,
      "target": 102
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Corticosteroids (methylprednisolone) and adrenocorticotropic hormone (ACTH) have anti-inﬂammatory and immunomodulatory effects and are typically used to treat acute relapse to hasten the recovery (Berkovich 2013).",
      "key": "c6b416ba76e3fec4a8e9bf8061bea77b",
      "line": 305,
      "relation": "decreases",
      "source": 9,
      "target": 140
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Corticosteroids (methylprednisolone) and adrenocorticotropic hormone (ACTH) have anti-inﬂammatory and immunomodulatory effects and are typically used to treat acute relapse to hasten the recovery (Berkovich 2013).",
      "key": "55c30447b2565c817d8366452e04f792",
      "line": 308,
      "relation": "isA",
      "source": 9,
      "target": 12
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Corticosteroids (methylprednisolone) and adrenocorticotropic hormone (ACTH) have anti-inﬂammatory and immunomodulatory effects and are typically used to treat acute relapse to hasten the recovery (Berkovich 2013).",
      "key": "ed8f3d0b4787acdba52bf1ad3602a85d",
      "line": 303,
      "relation": "decreases",
      "source": 18,
      "target": 102
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Corticosteroids (methylprednisolone) and adrenocorticotropic hormone (ACTH) have anti-inﬂammatory and immunomodulatory effects and are typically used to treat acute relapse to hasten the recovery (Berkovich 2013).",
      "key": "83c0d5dcf4b415d3f505a546411d4fad",
      "line": 306,
      "relation": "decreases",
      "source": 18,
      "target": 140
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Corticosteroids (methylprednisolone) and adrenocorticotropic hormone (ACTH) have anti-inﬂammatory and immunomodulatory effects and are typically used to treat acute relapse to hasten the recovery (Berkovich 2013).",
      "key": "aa1ba6df1d878d1ebe304341be45043c",
      "line": 309,
      "relation": "isA",
      "source": 18,
      "target": 12
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Corticosteroids (methylprednisolone) and adrenocorticotropic hormone (ACTH) have anti-inﬂammatory and immunomodulatory effects and are typically used to treat acute relapse to hasten the recovery (Berkovich 2013).",
      "key": "ba65d38887ae90b3636c3313a55574ed",
      "line": 304,
      "relation": "decreases",
      "source": 23,
      "target": 102
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Corticosteroids (methylprednisolone) and adrenocorticotropic hormone (ACTH) have anti-inﬂammatory and immunomodulatory effects and are typically used to treat acute relapse to hasten the recovery (Berkovich 2013).",
      "key": "4cacd52b15d304fe1524d14fc75d6f12",
      "line": 307,
      "relation": "decreases",
      "source": 23,
      "target": 140
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Corticosteroids (methylprednisolone) and adrenocorticotropic hormone (ACTH) have anti-inﬂammatory and immunomodulatory effects and are typically used to treat acute relapse to hasten the recovery (Berkovich 2013).",
      "key": "d14a566240bc3964112e6493c03e653e",
      "line": 310,
      "relation": "isA",
      "source": 23,
      "target": 12
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Interferons (IFNs) are endogenous proteins that are involved in immune response against viral and bacterial agents and were the ﬁrst class of disease modifying agents developed for treatment of MS.",
      "key": "769ac06ad16a6d78c3ed787d4c52b109",
      "line": 315,
      "relation": "isA",
      "source": 87,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Interferons (IFNs) are endogenous proteins that are involved in immune response against viral and bacterial agents and were the ﬁrst class of disease modifying agents developed for treatment of MS.",
      "key": "74aa514338def18a084319fcca2c0ad5",
      "line": 316,
      "relation": "isA",
      "source": 87,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Interferons (IFNs) are endogenous proteins that are involved in immune response against viral and bacterial agents and were the ﬁrst class of disease modifying agents developed for treatment of MS.",
      "key": "e93d8609501ffc7f61371e32953697d0",
      "line": 317,
      "relation": "decreases",
      "source": 87,
      "target": 98
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The beta-interferons (IFN-b) have multiple actions including stabilizing the BBB thereby limiting the entry of T cells into the CNS, modulating T- and B-cell function, and altering the expression of cytokines (Yong et al. 1998; Weber et al. 1999; Dhib-Jalbut 2002).",
      "key": "6c910181a4fd541822584940a2fda20c",
      "line": 322,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "Peripheral Nervous System",
            "namespace": "MESH"
          },
          "toLoc": {
            "name": "Central Nervous System",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "decreases",
      "source": 73,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The beta-interferons (IFN-b) have multiple actions including stabilizing the BBB thereby limiting the entry of T cells into the CNS, modulating T- and B-cell function, and altering the expression of cytokines (Yong et al. 1998; Weber et al. 1999; Dhib-Jalbut 2002).",
      "key": "12f7ee4cd94822bcd18a30159b6ce112",
      "line": 324,
      "object": {
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 73,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The beta-interferons (IFN-b) have multiple actions including stabilizing the BBB thereby limiting the entry of T cells into the CNS, modulating T- and B-cell function, and altering the expression of cytokines (Yong et al. 1998; Weber et al. 1999; Dhib-Jalbut 2002).",
      "key": "9490690e5654df758efb2e2bc6e4bad3",
      "line": 323,
      "relation": "association",
      "source": 73,
      "target": 25
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The beta-interferons (IFN-b) have multiple actions including stabilizing the BBB thereby limiting the entry of T cells into the CNS, modulating T- and B-cell function, and altering the expression of cytokines (Yong et al. 1998; Weber et al. 1999; Dhib-Jalbut 2002).",
      "key": "e3f36d31bcdf349d4518ef61c1b4569c",
      "line": 325,
      "object": {
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 73,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The beta-interferons (IFN-b) have multiple actions including stabilizing the BBB thereby limiting the entry of T cells into the CNS, modulating T- and B-cell function, and altering the expression of cytokines (Yong et al. 1998; Weber et al. 1999; Dhib-Jalbut 2002).",
      "key": "591d4d1207cb58668374fcf64d41daf9",
      "line": 326,
      "relation": "regulates",
      "source": 73,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The beta-interferons (IFN-b) have multiple actions including stabilizing the BBB thereby limiting the entry of T cells into the CNS, modulating T- and B-cell function, and altering the expression of cytokines (Yong et al. 1998; Weber et al. 1999; Dhib-Jalbut 2002).",
      "key": "71c204a9dbc33fb27efe66b86343e175",
      "line": 327,
      "relation": "regulates",
      "source": 73,
      "target": 46
    },
    {
      "annotations": {
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Both IFNb1a and IFN-b1b have shown similar efﬁcacy and are considered ﬁrst line agents for treating patients with relapsing MS and CIS (Rudick et al. 1997).",
      "key": "b58113027ed3bf95e94a54b3d067a4b6",
      "line": 332,
      "relation": "decreases",
      "source": 73,
      "target": 102
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The side effects of beta-interferon include ﬂu-like symptoms, depression, liver enzyme elevation, thyroid abnormalities, leukopenia or anemia, and injection site reactions (Rudick et al. 1997).",
      "key": "e47a6d6801f0454e45948d5fe66b9ff3",
      "line": 336,
      "relation": "increases",
      "source": 73,
      "target": 97
    },
    {
      "annotations": {
        "Anatomy": {
          "liver": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The side effects of beta-interferon include ﬂu-like symptoms, depression, liver enzyme elevation, thyroid abnormalities, leukopenia or anemia, and injection site reactions (Rudick et al. 1997).",
      "key": "af44c709998790483447ee284447e809",
      "line": 338,
      "relation": "increases",
      "source": 73,
      "target": 92
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The side effects of beta-interferon include ﬂu-like symptoms, depression, liver enzyme elevation, thyroid abnormalities, leukopenia or anemia, and injection site reactions (Rudick et al. 1997).",
      "key": "df09cc1a212c7974348d01c32583f090",
      "line": 340,
      "relation": "increases",
      "source": 73,
      "target": 104
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The side effects of beta-interferon include ﬂu-like symptoms, depression, liver enzyme elevation, thyroid abnormalities, leukopenia or anemia, and injection site reactions (Rudick et al. 1997).",
      "key": "79ba60cf1c8c3975131628200d96891d",
      "line": 341,
      "relation": "increases",
      "source": 73,
      "target": 107
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The side effects of beta-interferon include ﬂu-like symptoms, depression, liver enzyme elevation, thyroid abnormalities, leukopenia or anemia, and injection site reactions (Rudick et al. 1997).",
      "key": "71cd1d788e41ba81eee84eb22257b46c",
      "line": 342,
      "relation": "increases",
      "source": 73,
      "target": 134
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The beta-interferons (IFN-b) have multiple actions including stabilizing the BBB thereby limiting the entry of T cells into the CNS, modulating T- and B-cell function, and altering the expression of cytokines (Yong et al. 1998; Weber et al. 1999; Dhib-Jalbut 2002).",
      "key": "da7f837ce89e6d001b80dbe94de9cfd4",
      "line": 323,
      "relation": "association",
      "source": 25,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Glatiramer acetate (GA) or Copolymer 1 is a synthetic complex of four amino acids that mimics myelin basic protein (MBP), one of the autoantigens targeted by the T cells.",
      "key": "dde8e2d694d6f4d169d78115b593989e",
      "line": 347,
      "relation": "association",
      "source": 29,
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Due to its structural similarity to MBP, GA blocks the formation of myelin reactive T cells and induces GA-speciﬁc regulatory T-cell expression and Th2 antiinﬂammatory cytokine production (bystander suppression) (Wolinsky 1995; Rudick et al. 1997; Gran et al. 2000; Dhib-Jalbut 2002; Ruggieri et al. 2007).",
      "key": "fb5c36d04b9f08e47f05e1add2475b37",
      "line": 353,
      "relation": "decreases",
      "source": 29,
      "target": 64
    },
    {
      "key": "f3b8c3ca5f9413093e842febfa3a092e",
      "relation": "partOf",
      "source": 29,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Due to its structural similarity to MBP, GA blocks the formation of myelin reactive T cells and induces GA-speciﬁc regulatory T-cell expression and Th2 antiinﬂammatory cytokine production (bystander suppression) (Wolinsky 1995; Rudick et al. 1997; Gran et al. 2000; Dhib-Jalbut 2002; Ruggieri et al. 2007).",
      "key": "45ba7f16ab7674551f21fcdea7d8d6ee",
      "line": 354,
      "relation": "increases",
      "source": 29,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Due to its structural similarity to MBP, GA blocks the formation of myelin reactive T cells and induces GA-speciﬁc regulatory T-cell expression and Th2 antiinﬂammatory cytokine production (bystander suppression) (Wolinsky 1995; Rudick et al. 1997; Gran et al. 2000; Dhib-Jalbut 2002; Ruggieri et al. 2007).",
      "key": "5ea8de05f5462042cb16f35a27ae0604",
      "line": 355,
      "relation": "increases",
      "source": 29,
      "target": 48
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The side effect proﬁle of GA is, however, more favorable and includes local injection site reactions, post injection reaction (ﬂushing, chest tightness, palpitation, and dyspnea within minutes of injection with spontaneous resolution) and rare lipoatrophy with prolonged use.",
      "key": "2beba3cacc6a9afe128a216402e36fec",
      "line": 361,
      "relation": "increases",
      "source": 29,
      "target": 134
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The side effect proﬁle of GA is, however, more favorable and includes local injection site reactions, post injection reaction (ﬂushing, chest tightness, palpitation, and dyspnea within minutes of injection with spontaneous resolution) and rare lipoatrophy with prolonged use.",
      "key": "ebf62698d2984573d2de1b049b470afe",
      "line": 362,
      "relation": "increases",
      "source": 29,
      "target": 125
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The side effect proﬁle of GA is, however, more favorable and includes local injection site reactions, post injection reaction (ﬂushing, chest tightness, palpitation, and dyspnea within minutes of injection with spontaneous resolution) and rare lipoatrophy with prolonged use.",
      "key": "5e0dfe3f272b1004aa13119efe04102b",
      "line": 363,
      "relation": "increases",
      "source": 29,
      "target": 116
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The side effect proﬁle of GA is, however, more favorable and includes local injection site reactions, post injection reaction (ﬂushing, chest tightness, palpitation, and dyspnea within minutes of injection with spontaneous resolution) and rare lipoatrophy with prolonged use.",
      "key": "5941248154f868071042c7846885da1f",
      "line": 364,
      "relation": "increases",
      "source": 29,
      "target": 129
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The side effect proﬁle of GA is, however, more favorable and includes local injection site reactions, post injection reaction (ﬂushing, chest tightness, palpitation, and dyspnea within minutes of injection with spontaneous resolution) and rare lipoatrophy with prolonged use.",
      "key": "c51d3202d85ecca8f1faf2e138d2789f",
      "line": 365,
      "relation": "increases",
      "source": 29,
      "target": 123
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The side effect proﬁle of GA is, however, more favorable and includes local injection site reactions, post injection reaction (ﬂushing, chest tightness, palpitation, and dyspnea within minutes of injection with spontaneous resolution) and rare lipoatrophy with prolonged use.",
      "key": "d8aa85fc8bc97b65baaa44d155ea16d3",
      "line": 366,
      "relation": "increases",
      "source": 29,
      "target": 127
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Glatiramer acetate (GA) or Copolymer 1 is a synthetic complex of four amino acids that mimics myelin basic protein (MBP), one of the autoantigens targeted by the T cells.",
      "key": "353f5e7c0b2871e5db22e2b9f62c1876",
      "line": 347,
      "relation": "association",
      "source": 82,
      "target": 29
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Glatiramer acetate (GA) or Copolymer 1 is a synthetic complex of four amino acids that mimics myelin basic protein (MBP), one of the autoantigens targeted by the T cells.",
      "key": "7bb796e4e877368c3450b5e1c4adaee9",
      "line": 348,
      "relation": "isA",
      "source": 82,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Due to its structural similarity to MBP, GA blocks the formation of myelin reactive T cells and induces GA-speciﬁc regulatory T-cell expression and Th2 antiinﬂammatory cytokine production (bystander suppression) (Wolinsky 1995; Rudick et al. 1997; Gran et al. 2000; Dhib-Jalbut 2002; Ruggieri et al. 2007).",
      "key": "5b0b0a7eb960030b24ab167a16229731",
      "line": 356,
      "relation": "decreases",
      "source": 48,
      "target": 140
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Natalizumab is a humanized monoclonal antibody that binds a4b1-integrin on lymphocytes blocking their interaction with VCAM-1 on endothelial cells thereby preventing the transmigration of lymphocytes across the BBB (Ransohoff 2007).",
      "key": "f119de81287014675023b68c66bc83b0",
      "line": 371,
      "relation": "isA",
      "source": 19,
      "target": 88
    },
    {
      "key": "e88573d9aa13037e3ea008d7f07c6e69",
      "relation": "partOf",
      "source": 19,
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The major safety concern with natalizumab is progressive multifocal leukoencephalopathy (PML), a serious potentially fatal opportunistic brain infection caused by reactivation of JC virus (Yousry et al. 2006).",
      "key": "e332661e6b6d7e0c3b32b791ee63fea4",
      "line": 379,
      "relation": "increases",
      "source": 19,
      "target": 101
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Natalizumab is a humanized monoclonal antibody that binds a4b1-integrin on lymphocytes blocking their interaction with VCAM-1 on endothelial cells thereby preventing the transmigration of lymphocytes across the BBB (Ransohoff 2007).",
      "key": "4bd7e512e0fc72dd681bd155508bfc9e",
      "line": 372,
      "relation": "decreases",
      "source": 63,
      "target": 66
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Natalizumab is a humanized monoclonal antibody that binds a4b1-integrin on lymphocytes blocking their interaction with VCAM-1 on endothelial cells thereby preventing the transmigration of lymphocytes across the BBB (Ransohoff 2007).",
      "key": "e3593113d27398045c74d8112580a140",
      "line": 374,
      "relation": "decreases",
      "source": 63,
      "target": 60
    },
    {
      "key": "9e7eafeba0458160ffb14909788b1003",
      "relation": "partOf",
      "source": 80,
      "target": 63
    },
    {
      "key": "762e9443c19aa4eec42725e0fea58a3a",
      "relation": "partOf",
      "source": 80,
      "target": 66
    },
    {
      "key": "afe39d8e02fcae4d7de24ee0f60c4412",
      "relation": "partOf",
      "source": 81,
      "target": 63
    },
    {
      "key": "ba53b84d7f44336147eab26076479141",
      "relation": "partOf",
      "source": 81,
      "target": 66
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Natalizumab is a humanized monoclonal antibody that binds a4b1-integrin on lymphocytes blocking their interaction with VCAM-1 on endothelial cells thereby preventing the transmigration of lymphocytes across the BBB (Ransohoff 2007).",
      "key": "8426c336f2bf530948068abc77565d69",
      "line": 373,
      "relation": "increases",
      "source": 66,
      "target": 60
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The major safety concern with natalizumab is progressive multifocal leukoencephalopathy (PML), a serious potentially fatal opportunistic brain infection caused by reactivation of JC virus (Yousry et al. 2006).",
      "key": "49918f8651bd165f86451748bd960b1c",
      "line": 381,
      "relation": "increases",
      "source": 30,
      "target": 101
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Mitoxantrone is a synthetic anthracendione antineoplastic agent; its immunomodulatory effects include suppression of T and B lymphocytes and macrophage proliferation.",
      "key": "97c85fddbb7a22d186e4b9e929f3d5c2",
      "line": 387,
      "relation": "isA",
      "source": 14,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Mitoxantrone is a synthetic anthracendione antineoplastic agent; its immunomodulatory effects include suppression of T and B lymphocytes and macrophage proliferation.",
      "key": "2d234d5d39a50c3611e409c0ee8a0540",
      "line": 388,
      "relation": "decreases",
      "source": 14,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Mitoxantrone is a synthetic anthracendione antineoplastic agent; its immunomodulatory effects include suppression of T and B lymphocytes and macrophage proliferation.",
      "key": "dfadfbb85c0c530a905504caad2b9458",
      "line": 389,
      "relation": "decreases",
      "source": 14,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Mitoxantrone is a synthetic anthracendione antineoplastic agent; its immunomodulatory effects include suppression of T and B lymphocytes and macrophage proliferation.",
      "key": "fcc7eff7417558ea31aa0a59407a6f8b",
      "line": 390,
      "relation": "decreases",
      "source": 14,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Mitoxantrone is indicated for reducing disability and relapse frequency in patients with worsening relapsing remitting and secondary-progressive MS, however, its use has been limited due to risk of dose-related cardiotoxicity and treatment-related leukemia (Fox 2006).",
      "key": "b9150ed21136bfef5d833925aa25f496",
      "line": 395,
      "relation": "decreases",
      "source": 14,
      "target": 102
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Mitoxantrone is indicated for reducing disability and relapse frequency in patients with worsening relapsing remitting and secondary-progressive MS, however, its use has been limited due to risk of dose-related cardiotoxicity and treatment-related leukemia (Fox 2006).",
      "key": "77b468e87ac8a92bd5ddc409aa902d0c",
      "line": 396,
      "relation": "decreases",
      "source": 14,
      "target": 103
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Mitoxantrone is indicated for reducing disability and relapse frequency in patients with worsening relapsing remitting and secondary-progressive MS, however, its use has been limited due to risk of dose-related cardiotoxicity and treatment-related leukemia (Fox 2006).",
      "key": "b595f0f45fd3aefcf22a470552e9f2ba",
      "line": 397,
      "relation": "increases",
      "source": 14,
      "target": 138
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Mitoxantrone is indicated for reducing disability and relapse frequency in patients with worsening relapsing remitting and secondary-progressive MS, however, its use has been limited due to risk of dose-related cardiotoxicity and treatment-related leukemia (Fox 2006).",
      "key": "a2a79a1497f7c07db687ebcc285a82c7",
      "line": 398,
      "relation": "increases",
      "source": 14,
      "target": 106
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Three new oral medications have recently become available for treatment of relapsing MS: ﬁngolimod, teriﬂunomide, and dimethylfumarate.",
      "key": "42d635c0272d267e586c298036143409",
      "line": 403,
      "relation": "decreases",
      "source": 10,
      "target": 102
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Fingolimod is a sphingosine-1-phosphate receptor (S1P1) modulator and was the ﬁrst oral drug approved for treatment of MS.",
      "key": "c478d0a4400e3055dc411bf200a7ea49",
      "line": 410,
      "relation": "regulates",
      "source": 10,
      "target": 84
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Fingolimod is a sphingosine-1-phosphate receptor (S1P1) modulator and was the ﬁrst oral drug approved for treatment of MS.",
      "key": "1e18ade9f6b8d66b8d2809c9c915bda3",
      "line": 411,
      "relation": "decreases",
      "source": 10,
      "target": 98
    },
    {
      "key": "3887480766ab9e5e498dba02efa19c82",
      "relation": "partOf",
      "source": 10,
      "target": 62
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The potential side effects of ﬁngolimod include ﬁrst dose bradycardia, atrioventricular block, herpes virus infection, macular edema, elevated blood pressure, and a reported cases of PML (Cohen et al. 2010; Kappos et al. 2010; Samson 2013; Calic et al. 2015).",
      "key": "e035c6796e1bcbc2b240dfa9b4d9ab46",
      "line": 421,
      "relation": "increases",
      "source": 10,
      "target": 122
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The potential side effects of ﬁngolimod include ﬁrst dose bradycardia, atrioventricular block, herpes virus infection, macular edema, elevated blood pressure, and a reported cases of PML (Cohen et al. 2010; Kappos et al. 2010; Samson 2013; Calic et al. 2015).",
      "key": "871cf1e5587fcbfd64320219f61584a6",
      "line": 422,
      "relation": "increases",
      "source": 10,
      "target": 93
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The potential side effects of ﬁngolimod include ﬁrst dose bradycardia, atrioventricular block, herpes virus infection, macular edema, elevated blood pressure, and a reported cases of PML (Cohen et al. 2010; Kappos et al. 2010; Samson 2013; Calic et al. 2015).",
      "key": "d1c998fc815e3a846081e6039555015e",
      "line": 423,
      "relation": "increases",
      "source": 10,
      "target": 96
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The potential side effects of ﬁngolimod include ﬁrst dose bradycardia, atrioventricular block, herpes virus infection, macular edema, elevated blood pressure, and a reported cases of PML (Cohen et al. 2010; Kappos et al. 2010; Samson 2013; Calic et al. 2015).",
      "key": "04176cdccbe38c89663f6891055b8d25",
      "line": 424,
      "relation": "increases",
      "source": 10,
      "target": 119
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The potential side effects of ﬁngolimod include ﬁrst dose bradycardia, atrioventricular block, herpes virus infection, macular edema, elevated blood pressure, and a reported cases of PML (Cohen et al. 2010; Kappos et al. 2010; Samson 2013; Calic et al. 2015).",
      "key": "69b5e79c612ccc9969afb0bba1e882ca",
      "line": 425,
      "relation": "increases",
      "source": 10,
      "target": 53
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The potential side effects of ﬁngolimod include ﬁrst dose bradycardia, atrioventricular block, herpes virus infection, macular edema, elevated blood pressure, and a reported cases of PML (Cohen et al. 2010; Kappos et al. 2010; Samson 2013; Calic et al. 2015).",
      "key": "1f1119087f8a69b8ca56ee972c39c71a",
      "line": 426,
      "relation": "increases",
      "source": 10,
      "target": 101
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Three new oral medications have recently become available for treatment of relapsing MS: ﬁngolimod, teriﬂunomide, and dimethylfumarate.",
      "key": "b3f09cfb7c66a459bbb6e9ca1a616380",
      "line": 404,
      "relation": "decreases",
      "source": 17,
      "target": 102
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Teriﬂunomide is an active metabolite of leﬂunomide (a drug used to treat rheumatoid arthritis) and is an inhibitor of enzyme dihyrdro-orotate dehydrogenase (DHODH) which interferes with denovo synthesis of pyrimidine in rapidly dividing cells (Oh and O’Connor 2013).",
      "key": "79ee6a41e2c53c364a1265aab9f4961d",
      "line": 432,
      "relation": "decreases",
      "source": 17,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Its antiinﬂammatory effect in MS is believed to be mediated by reducing the activity of proliferating T and B lymphocytes.",
      "key": "413c94b951bac44b7f1fe9c5ba60f422",
      "line": 437,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 17,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Its antiinﬂammatory effect in MS is believed to be mediated by reducing the activity of proliferating T and B lymphocytes.",
      "key": "19016a0018bfd5822c2c5c330da5ae1d",
      "line": 438,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 17,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Its antiinﬂammatory effect in MS is believed to be mediated by reducing the activity of proliferating T and B lymphocytes.",
      "key": "042c7e155dd47bde9291df176ec21713",
      "line": 439,
      "relation": "decreases",
      "source": 17,
      "target": 140
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The short-term side effects of teriﬂunomide are relatively mild and include hair loss, headache, diarrhea, and elevated liver enzymes (O’Connor et al. 2011).",
      "key": "7d81f9351e9ad3a0dd4d3e395343acc9",
      "line": 449,
      "relation": "increases",
      "source": 17,
      "target": 136
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The short-term side effects of teriﬂunomide are relatively mild and include hair loss, headache, diarrhea, and elevated liver enzymes (O’Connor et al. 2011).",
      "key": "369a889c543cd31d28cae6f2b144e16d",
      "line": 450,
      "relation": "increases",
      "source": 17,
      "target": 126
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The short-term side effects of teriﬂunomide are relatively mild and include hair loss, headache, diarrhea, and elevated liver enzymes (O’Connor et al. 2011).",
      "key": "f059b09e6ef9b9693304020f65b8ce09",
      "line": 451,
      "relation": "increases",
      "source": 17,
      "target": 105
    },
    {
      "annotations": {
        "Anatomy": {
          "liver": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The short-term side effects of teriﬂunomide are relatively mild and include hair loss, headache, diarrhea, and elevated liver enzymes (O’Connor et al. 2011).",
      "key": "d3b85d5a4cccf30e8934adc91cebdfa4",
      "line": 453,
      "relation": "increases",
      "source": 17,
      "target": 92
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Reduction in lymphocyte and neutrophil counts, elevated blood pressure, and a single case of latent tuberculosis are some of the other side effects reported (O’Connor et al. 2011; Confavreux et al. 2014).",
      "key": "28a40bd29d251bba987722ea0ed37447",
      "line": 459,
      "relation": "decreases",
      "source": 17,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Reduction in lymphocyte and neutrophil counts, elevated blood pressure, and a single case of latent tuberculosis are some of the other side effects reported (O’Connor et al. 2011; Confavreux et al. 2014).",
      "key": "95ea04e6ffab974f999cba6afb5cfaa6",
      "line": 460,
      "relation": "decreases",
      "source": 17,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Reduction in lymphocyte and neutrophil counts, elevated blood pressure, and a single case of latent tuberculosis are some of the other side effects reported (O’Connor et al. 2011; Confavreux et al. 2014).",
      "key": "90c16f9ec157fd500e7996e4221f28ba",
      "line": 461,
      "relation": "increases",
      "source": 17,
      "target": 53
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Reduction in lymphocyte and neutrophil counts, elevated blood pressure, and a single case of latent tuberculosis are some of the other side effects reported (O’Connor et al. 2011; Confavreux et al. 2014).",
      "key": "8c9314227f9f2aa0b3f6992e0e780ffc",
      "line": 462,
      "relation": "increases",
      "source": 17,
      "target": 110
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Three new oral medications have recently become available for treatment of relapsing MS: ﬁngolimod, teriﬂunomide, and dimethylfumarate.",
      "key": "69f45501b321d8e4958fec1b091f8db2",
      "line": 405,
      "relation": "decreases",
      "source": 3,
      "target": 102
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Dimethylfumarate (DMF) or BG12 is the latest oral therapy to be approved for treatment of MS.",
      "key": "5839ec85d723068181f3fc96a11bb987",
      "line": 467,
      "relation": "decreases",
      "source": 3,
      "target": 98
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The mechanism of action of DMF involves inhibition of proinﬂammatory pathways via activation of nuclear factor erythroid 2-related factor 2 (Nrf-2) antioxidant response pathway (Linker et al. 2011).",
      "key": "27b8a7c4b3925afa56330dd4c7f71af6",
      "line": 472,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 3,
      "target": 83
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The most common side effect with DMF include nausea, diarrhea, abdominal pain which can be minimized by taking the medication with food and ﬂushing which can be reduced by aspirin (Gold et al. 2012; Fox et al. 2014).",
      "key": "c9aadb8748b75eddce94056d1a0c51fd",
      "line": 478,
      "relation": "increases",
      "source": 3,
      "target": 128
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The most common side effect with DMF include nausea, diarrhea, abdominal pain which can be minimized by taking the medication with food and ﬂushing which can be reduced by aspirin (Gold et al. 2012; Fox et al. 2014).",
      "key": "db81cbad550f3f532ba2ab8651da3c5e",
      "line": 479,
      "relation": "increases",
      "source": 3,
      "target": 105
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The most common side effect with DMF include nausea, diarrhea, abdominal pain which can be minimized by taking the medication with food and ﬂushing which can be reduced by aspirin (Gold et al. 2012; Fox et al. 2014).",
      "key": "c04270aef5b8a454f5bc1e646cad7168",
      "line": 480,
      "relation": "increases",
      "source": 3,
      "target": 112
    },
    {
      "key": "126eebbdb4d8ba723d0c05c91164ddc4",
      "relation": "partOf",
      "source": 3,
      "target": 68
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The most common side effect with DMF include nausea, diarrhea, abdominal pain which can be minimized by taking the medication with food and ﬂushing which can be reduced by aspirin (Gold et al. 2012; Fox et al. 2014).",
      "key": "a2964fcef42eb46368312698ecfad692",
      "line": 482,
      "relation": "increases",
      "source": 3,
      "target": 125
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Lymphopenia may occur although no increased infection risk was observed in phase 3 studies (Fox et al. 2012; Gold et al. 2012).",
      "key": "6ea3cdd171f42575bf1ad7fc5334077d",
      "line": 488,
      "relation": "increases",
      "source": 3,
      "target": 108
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "There has been a recent report of a fatal case of PML in a patient with multiple sclerosis treated with dimethyl fumarate (FDA Drug Safety Communication,2014)",
      "key": "b09b55fe5cb5fd7eb5f0a0ada3350b10",
      "line": 493,
      "relation": "increases",
      "source": 3,
      "target": 101
    },
    {
      "key": "32db55018b907d43f70e4bff435ac993",
      "relation": "partOf",
      "source": 84,
      "target": 62
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "By binding to S1P1 receptor on the T cells, it prevents emigration of activated T cells from lymph nodes thereby limiting their entry into the CNS (Chiba et al. 1998; Pelletier and Haﬂer 2012).",
      "key": "3a17b7a73842cf27d1e46cbd7547a32d",
      "line": 416,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "Lymph Nodes",
            "namespace": "MESH"
          },
          "toLoc": {
            "name": "Central Nervous System",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "decreases",
      "source": 62,
      "subject": {
        "location": {
          "name": "T-Lymphocytes",
          "namespace": "MESH"
        }
      },
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Teriﬂunomide is an active metabolite of leﬂunomide (a drug used to treat rheumatoid arthritis) and is an inhibitor of enzyme dihyrdro-orotate dehydrogenase (DHODH) which interferes with denovo synthesis of pyrimidine in rapidly dividing cells (Oh and O’Connor 2013).",
      "key": "af925f635e42f034b4a6b0ff5c50ac5d",
      "line": 431,
      "relation": "decreases",
      "source": 13,
      "target": 120
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Leﬂunomide is converted almost entirely into teriﬂunomide after absorption and taken at the recommended doses, both drugs result in similar plasma concentration of teriﬂunomide (AUBAGIO (teriﬂunomide) Prescibing information. 2014).",
      "key": "ed5d7738ea940eea607b85e6b61dc717",
      "line": 444,
      "relation": "increases",
      "source": 13,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "Teriﬂunomide is an active metabolite of leﬂunomide (a drug used to treat rheumatoid arthritis) and is an inhibitor of enzyme dihyrdro-orotate dehydrogenase (DHODH) which interferes with denovo synthesis of pyrimidine in rapidly dividing cells (Oh and O’Connor 2013).",
      "key": "ef9974ec6ed43767bfe8e1e50b68d708",
      "line": 433,
      "relation": "decreases",
      "source": 72,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The mechanism of action of DMF involves inhibition of proinﬂammatory pathways via activation of nuclear factor erythroid 2-related factor 2 (Nrf-2) antioxidant response pathway (Linker et al. 2011).",
      "key": "78122eede7d25bedb4a1ea4bd20aed85",
      "line": 473,
      "relation": "decreases",
      "source": 83,
      "subject": {
        "modifier": "Activity"
      },
      "target": 140
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The most common side effect with DMF include nausea, diarrhea, abdominal pain which can be minimized by taking the medication with food and ﬂushing which can be reduced by aspirin (Gold et al. 2012; Fox et al. 2014).",
      "key": "7e0d40ffea496c9a044bb9851e64b60e",
      "line": 481,
      "relation": "decreases",
      "source": 68,
      "target": 112
    },
    {
      "key": "9a8c3dafd1713ccb569f0f56be955bca",
      "relation": "partOf",
      "source": 11,
      "target": 68
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Garg N",
          "Smith TW"
        ],
        "date": "2015-09-01",
        "db": "PubMed",
        "db_id": "26445701",
        "db_name": "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.",
        "first": "Garg N",
        "journal": "Brain and behavior",
        "last": "Smith TW",
        "pages": "e00362",
        "volume": "5"
      },
      "evidence": "The most common side effect with DMF include nausea, diarrhea, abdominal pain which can be minimized by taking the medication with food and ﬂushing which can be reduced by aspirin (Gold et al. 2012; Fox et al. 2014).",
      "key": "a0671c4b772bbc641549b0edbfa988c8",
      "line": 483,
      "relation": "decreases",
      "source": 36,
      "target": 125
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"antibacterial agent\")",
      "concept": {
        "name": "antibacterial agent",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "3a12e84bd0b12726c8c7a6d35ddaa466"
    },
    {
      "bel": "a(CHEBI:\"antineoplastic agent\")",
      "concept": {
        "name": "antineoplastic agent",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "c5ecd61a8f9c6bbb6c62472cf769e2ce"
    },
    {
      "bel": "a(CHEBI:\"antiviral agent\")",
      "concept": {
        "name": "antiviral agent",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "a6172ccd2ae78b81ed069d369b9a5aae"
    },
    {
      "bel": "a(CHEBI:\"dimethyl fumarate\")",
      "concept": {
        "name": "dimethyl fumarate",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "1dfb50778023775ca326ed078cc1dd5b"
    },
    {
      "bel": "a(CHEBI:\"nitric oxide\")",
      "concept": {
        "name": "nitric oxide",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "da5a3d810aacb9c4649ec7df3b5f60d3"
    },
    {
      "bel": "a(CHEBI:\"omega-3 unsaturated fatty acyl-CoA(4-)\")",
      "concept": {
        "name": "omega-3 unsaturated fatty acyl-CoA(4-)",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "01722e0dce40b7d68b29138c4d625fa0"
    },
    {
      "bel": "a(CHEBI:\"sodium salt\")",
      "concept": {
        "name": "sodium salt",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "62f776ad609daa8f1712f2fd145f2acb"
    },
    {
      "bel": "a(CHEBI:\"vitamin A\")",
      "concept": {
        "name": "vitamin A",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "481eff41e87309e7ec03f1b1d3f8bc2a"
    },
    {
      "bel": "a(CHEBI:\"vitamin D\")",
      "concept": {
        "name": "vitamin D",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "fd208ca9f82e3458fe111072206d4e83"
    },
    {
      "bel": "a(CHEBI:corticosteroid)",
      "concept": {
        "name": "corticosteroid",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "a468686acdbd9b5763eec60c73e99320"
    },
    {
      "bel": "a(CHEBI:fingolimod)",
      "concept": {
        "name": "fingolimod",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "f8331f01e17dd4930a9ec364d4b4e58b"
    },
    {
      "bel": "a(CHEBI:food)",
      "concept": {
        "name": "food",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "3b51ba1d7eb308e5431da8fd8f759185"
    },
    {
      "bel": "a(CHEBI:immunomodulator)",
      "concept": {
        "name": "immunomodulator",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "e147c508e42eb4eddb3298468e9f2570"
    },
    {
      "bel": "a(CHEBI:leflunomide)",
      "concept": {
        "name": "leflunomide",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "848d52e2d3479f1424364fd1df184bb2"
    },
    {
      "bel": "a(CHEBI:mitoxantrone)",
      "concept": {
        "name": "mitoxantrone",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "58cc4c28580fbf4cdecc4c55261ae9a7"
    },
    {
      "bel": "a(CHEBI:polyphenol)",
      "concept": {
        "name": "polyphenol",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "fdfacabcdaa49ee91452cbdae35ed2c4"
    },
    {
      "bel": "a(CHEBI:salt)",
      "concept": {
        "name": "salt",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "4f956b43dbfaa99dd69d7a3a27503bb2"
    },
    {
      "bel": "a(CHEBI:teriflunomide)",
      "concept": {
        "name": "teriflunomide",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "1a81c1c7d07d03bbd3e73a96400ce941"
    },
    {
      "bel": "a(DRUGBANK:Methylprednisolone)",
      "concept": {
        "name": "Methylprednisolone",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "77d5836bc79dbd21be1a657f70824b12"
    },
    {
      "bel": "a(DRUGBANK:Natalizumab)",
      "concept": {
        "name": "Natalizumab",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "aa5b6e671b82a62bbe1c8f71f964055a"
    },
    {
      "bel": "a(GO:\"myelin sheath\")",
      "concept": {
        "name": "myelin sheath",
        "namespace": "GO"
      },
      "function": "Abundance",
      "id": "bf6321e3579542c2ca199fdb7abf3275"
    },
    {
      "bel": "a(HP:\"Focal white matter lesions\")",
      "concept": {
        "name": "Focal white matter lesions",
        "namespace": "HP"
      },
      "function": "Abundance",
      "id": "749fd3f6cf06dcfd7667796ea8cfb8fa"
    },
    {
      "bel": "a(HP:\"Senile plaques\")",
      "concept": {
        "name": "Senile plaques",
        "namespace": "HP"
      },
      "function": "Abundance",
      "id": "9d3ac738642af7d6540d369d45a429e5"
    },
    {
      "bel": "a(MESH:\"Adrenocorticotropic Hormone\")",
      "concept": {
        "name": "Adrenocorticotropic Hormone",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "b809fde658447df52e1cb116e0c095e4"
    },
    {
      "bel": "a(MESH:\"B-Lymphocytes\")",
      "concept": {
        "name": "B-Lymphocytes",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "f58463c9771eaea79cce530465284035"
    },
    {
      "bel": "a(MESH:\"Blood-Brain Barrier\")",
      "concept": {
        "name": "Blood-Brain Barrier",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "63dcf0f7f45e2c3862eb5a77da5f2627"
    },
    {
      "bel": "a(MESH:\"CD4-Positive T-Lymphocytes\")",
      "concept": {
        "name": "CD4-Positive T-Lymphocytes",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "d26f55e472a40223e18fc717c6a1b55d"
    },
    {
      "bel": "a(MESH:\"CD8-Positive T-Lymphocytes\")",
      "concept": {
        "name": "CD8-Positive T-Lymphocytes",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "59b2f285d4c75c8c59127aa7c441658c"
    },
    {
      "bel": "a(MESH:\"Cell Adhesion Molecules\")",
      "concept": {
        "name": "Cell Adhesion Molecules",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "8f9c2f3217f187cb6562bdccae9c0dc8"
    },
    {
      "bel": "a(MESH:\"Glatiramer Acetate\")",
      "concept": {
        "name": "Glatiramer Acetate",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "b04c825e3baa4d90dcd627d862c6ed6e"
    },
    {
      "bel": "a(MESH:\"JC Virus\")",
      "concept": {
        "name": "JC Virus",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "1bc75dff190eb1586ebcd90ec1ecc1a2"
    },
    {
      "bel": "a(MESH:\"Plasma Cells\")",
      "concept": {
        "name": "Plasma Cells",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "976bf10c4cc8f617d3e0c46987664e6a"
    },
    {
      "bel": "a(MESH:\"T-Lymphocytes\")",
      "concept": {
        "name": "T-Lymphocytes",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "04840e346c8f8e46d6d4e5ed8f1b84c5"
    },
    {
      "bel": "a(MESH:\"Th1 Cells\")",
      "concept": {
        "name": "Th1 Cells",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "556e55bb1bfab9908230d383616f04ed"
    },
    {
      "bel": "a(MESH:\"Th17 Cells\")",
      "concept": {
        "name": "Th17 Cells",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "03f266f4a7d5b3028dd2af8637fe909f"
    },
    {
      "bel": "a(MESH:\"Th2 Cells\")",
      "concept": {
        "name": "Th2 Cells",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "f9aac88ef998325c524a95883639e711"
    },
    {
      "bel": "a(MESH:Aspirin)",
      "concept": {
        "name": "Aspirin",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "4717571db4a4d843f22145bb03fa45f5"
    },
    {
      "bel": "a(MESH:Autoantigens)",
      "concept": {
        "name": "Autoantigens",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "db19118b54c436d04d573bb68a5645ad"
    },
    {
      "bel": "a(MESH:Chemokines)",
      "concept": {
        "name": "Chemokines",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "9a02b9191c070440d07b7fd83cdc58e1"
    },
    {
      "bel": "a(MESH:Lymphocytes)",
      "concept": {
        "name": "Lymphocytes",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "05994a861f52857ee7dd98e839952695"
    },
    {
      "bel": "a(MESH:Microglia)",
      "concept": {
        "name": "Microglia",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "4ef490b325b2b1e33e41b4e22e1bd8c6"
    },
    {
      "bel": "a(MESH:Neutrophils)",
      "concept": {
        "name": "Neutrophils",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "994989dde1444ddb73e4c899a00aabc7"
    },
    {
      "bel": "a(MESH:Pyrimidines)",
      "concept": {
        "name": "Pyrimidines",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "92432183722d8e9a73ac30009c37077b"
    },
    {
      "bel": "a(MESH:Sanitation)",
      "concept": {
        "name": "Sanitation",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "273f07f884d1636d02b4b825252e91f5"
    },
    {
      "bel": "bp(GO:\"B cell cytokine production\")",
      "concept": {
        "name": "B cell cytokine production",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "9282fc3271a8bfc298517759c1483805"
    },
    {
      "bel": "bp(GO:\"T cell activation\")",
      "concept": {
        "name": "T cell activation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "6475795284a1f1c537342febd590bb31"
    },
    {
      "bel": "bp(GO:\"T cell cytokine production\")",
      "concept": {
        "name": "T cell cytokine production",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "bd1270b361e45ff65531650d8fa28e7d"
    },
    {
      "bel": "bp(GO:\"T-helper 17 cell differentiation\")",
      "concept": {
        "name": "T-helper 17 cell differentiation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "9483e2b856004e4f1742702176209b33"
    },
    {
      "bel": "bp(GO:\"T-helper 2 cell cytokine production\")",
      "concept": {
        "name": "T-helper 2 cell cytokine production",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "b894334c1764a0c896997ead8966967f"
    },
    {
      "bel": "bp(GO:\"complement activation\")",
      "concept": {
        "name": "complement activation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "c81d3c1b4b64cb916f209952fea071e6"
    },
    {
      "bel": "bp(GO:\"macrophage activation\")",
      "concept": {
        "name": "macrophage activation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "b4f30b2d638992803651eb8bd038b5e6"
    },
    {
      "bel": "bp(GO:\"macrophage proliferation\")",
      "concept": {
        "name": "macrophage proliferation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "786380553d770abdf0504f93307e11a2"
    },
    {
      "bel": "bp(GO:\"motor behavior\")",
      "concept": {
        "name": "motor behavior",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "a2dcc4ec00ebc4321e0089baccd16aa5"
    },
    {
      "bel": "bp(GO:\"positive regulation of blood pressure\")",
      "concept": {
        "name": "positive regulation of blood pressure",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "522dadf92389e5051ec075ea3df33623"
    },
    {
      "bel": "bp(GO:\"positive regulation of oligodendrocyte apoptotic process\")",
      "concept": {
        "name": "positive regulation of oligodendrocyte apoptotic process",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "8f089a87f8cb5c4c634cb037ba71e814"
    },
    {
      "bel": "bp(GO:\"sensory perception\")",
      "concept": {
        "name": "sensory perception",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "52781435a66c730be4fee87fe0d0eaef"
    },
    {
      "bel": "bp(GO:\"visual behavior\")",
      "concept": {
        "name": "visual behavior",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "f638353f0b6badc144a0ecb27d4c1779"
    },
    {
      "bel": "bp(GO:cognition)",
      "concept": {
        "name": "cognition",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "24220ec2073c35bcd945681ee9c6ea38"
    },
    {
      "bel": "bp(MESH:\"Molecular Mimicry\")",
      "concept": {
        "name": "Molecular Mimicry",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "85dfec86c9fc2f0fcc22f393e7aa04f7"
    },
    {
      "bel": "bp(MESH:\"Self Tolerance\")",
      "concept": {
        "name": "Self Tolerance",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "faaae905b240342d8073e076e1efdecd"
    },
    {
      "bel": "bp(MESH:\"Transendothelial and Transepithelial Migration\")",
      "concept": {
        "name": "Transendothelial and Transepithelial Migration",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "b51d5b4e993d69354b82edb87e0cb066"
    },
    {
      "bel": "bp(MESH:Immunity)",
      "concept": {
        "name": "Immunity",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "9e0bf623f2590a960b619d224ef1381a"
    },
    {
      "bel": "complex(a(CHEBI:fingolimod), p(HGNC:S1PR1))",
      "function": "Complex",
      "id": "374e88725140ee241d990c31ea3c5865",
      "members": [
        {
          "bel": "a(CHEBI:fingolimod)",
          "concept": {
            "name": "fingolimod",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "f8331f01e17dd4930a9ec364d4b4e58b"
        },
        {
          "bel": "p(HGNC:S1PR1)",
          "concept": {
            "name": "S1PR1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "790a4a883be37d698cd7f2676b3e0d49"
        }
      ]
    },
    {
      "bel": "complex(a(DRUGBANK:Natalizumab), p(HGNC:ITGA4), p(HGNC:ITGB1))",
      "function": "Complex",
      "id": "3dc85de7ec5deb7fddc7073e148056b3",
      "members": [
        {
          "bel": "a(DRUGBANK:Natalizumab)",
          "concept": {
            "name": "Natalizumab",
            "namespace": "DRUGBANK"
          },
          "function": "Abundance",
          "id": "aa5b6e671b82a62bbe1c8f71f964055a"
        },
        {
          "bel": "p(HGNC:ITGA4)",
          "concept": {
            "name": "ITGA4",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "5dd2353ec77585df3ddc7b475d39e72d"
        },
        {
          "bel": "p(HGNC:ITGB1)",
          "concept": {
            "name": "ITGB1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "ce18e44c941c45852f1a4a546a08b5fd"
        }
      ]
    },
    {
      "bel": "complex(a(GO:\"myelin sheath\"), a(MESH:\"T-Lymphocytes\"))",
      "function": "Complex",
      "id": "cfcdacb62ee681b034c8f5b947470654",
      "members": [
        {
          "bel": "a(GO:\"myelin sheath\")",
          "concept": {
            "name": "myelin sheath",
            "namespace": "GO"
          },
          "function": "Abundance",
          "id": "bf6321e3579542c2ca199fdb7abf3275"
        },
        {
          "bel": "a(MESH:\"T-Lymphocytes\")",
          "concept": {
            "name": "T-Lymphocytes",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "04840e346c8f8e46d6d4e5ed8f1b84c5"
        }
      ]
    },
    {
      "bel": "complex(a(MESH:\"Glatiramer Acetate\"), a(MESH:\"T-Lymphocytes\"))",
      "function": "Complex",
      "id": "08cab745c81b092413ad76a75be62541",
      "members": [
        {
          "bel": "a(MESH:\"Glatiramer Acetate\")",
          "concept": {
            "name": "Glatiramer Acetate",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "b04c825e3baa4d90dcd627d862c6ed6e"
        },
        {
          "bel": "a(MESH:\"T-Lymphocytes\")",
          "concept": {
            "name": "T-Lymphocytes",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "04840e346c8f8e46d6d4e5ed8f1b84c5"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:ITGA4), p(HGNC:ITGB1), p(HGNC:VCAM1))",
      "function": "Complex",
      "id": "8751fb4d39ede831f40dfbed34961857",
      "members": [
        {
          "bel": "p(HGNC:ITGA4)",
          "concept": {
            "name": "ITGA4",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "5dd2353ec77585df3ddc7b475d39e72d"
        },
        {
          "bel": "p(HGNC:ITGB1)",
          "concept": {
            "name": "ITGB1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "ce18e44c941c45852f1a4a546a08b5fd"
        },
        {
          "bel": "p(HGNC:VCAM1)",
          "concept": {
            "name": "VCAM1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "1f8295903afe529c3261018587ec7a88"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:VCAM1), p(MESH:\"Receptors, Very Late Antigen\"))",
      "function": "Complex",
      "id": "6530ffa1b7f803c4a0b3659882845e0d",
      "members": [
        {
          "bel": "p(HGNC:VCAM1)",
          "concept": {
            "name": "VCAM1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "1f8295903afe529c3261018587ec7a88"
        },
        {
          "bel": "p(MESH:\"Receptors, Very Late Antigen\")",
          "concept": {
            "name": "Receptors, Very Late Antigen",
            "namespace": "MESH"
          },
          "function": "Protein",
          "id": "a7570504f6d8c6303eeeb4a8dc4f3257"
        }
      ]
    },
    {
      "bel": "composite(a(CHEBI:\"dimethyl fumarate\"), a(CHEBI:food))",
      "function": "Composite",
      "id": "efa09cdd21d7ba00a33f2ca52fb3bb90",
      "members": [
        {
          "bel": "a(CHEBI:\"dimethyl fumarate\")",
          "concept": {
            "name": "dimethyl fumarate",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "1dfb50778023775ca326ed078cc1dd5b"
        },
        {
          "bel": "a(CHEBI:food)",
          "concept": {
            "name": "food",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "3b51ba1d7eb308e5431da8fd8f759185"
        }
      ]
    },
    {
      "bel": "g(HGNC:IL2RA)",
      "concept": {
        "name": "IL2RA",
        "namespace": "HGNC"
      },
      "function": "Gene",
      "id": "e70a305fb63d3ced4254104895817bad"
    },
    {
      "bel": "g(HGNC:IL7R)",
      "concept": {
        "name": "IL7R",
        "namespace": "HGNC"
      },
      "function": "Gene",
      "id": "c02011bd5373f82c0a81d278cf5b59ee"
    },
    {
      "bel": "g(HGNCGENEFAMILY:\"Histocompatibility complex\")",
      "concept": {
        "name": "Histocompatibility complex",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Gene",
      "id": "3c4f99aaeb95a1930d5b709b73c499c8"
    },
    {
      "bel": "p(HGNC:DHODH)",
      "concept": {
        "name": "DHODH",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "cdfa1f5047f4d1ea7d1f46ae3a802a08"
    },
    {
      "bel": "p(HGNC:IFNB1)",
      "concept": {
        "name": "IFNB1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "187da957c4e0c092e01fc85dd9da5fa4"
    },
    {
      "bel": "p(HGNC:IL10)",
      "concept": {
        "name": "IL10",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "e0c41f4b3cb8bef32af4e3217ba8aa12"
    },
    {
      "bel": "p(HGNC:IL17A)",
      "concept": {
        "name": "IL17A",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7565adaa388ec2dccc2d062833d6f622"
    },
    {
      "bel": "p(HGNC:IL1B)",
      "concept": {
        "name": "IL1B",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "cca08112d9fcf1a31015f1dbfc30b04c"
    },
    {
      "bel": "p(HGNC:IL2)",
      "concept": {
        "name": "IL2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "99fcd5fe54813ead0bd02d8a06f42173"
    },
    {
      "bel": "p(HGNC:IL4)",
      "concept": {
        "name": "IL4",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "4bf986cc68574441e53aac56e3621b28"
    },
    {
      "bel": "p(HGNC:IL5)",
      "concept": {
        "name": "IL5",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "282a47003e8a89a19850c2c304377390"
    },
    {
      "bel": "p(HGNC:ITGA4)",
      "concept": {
        "name": "ITGA4",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "5dd2353ec77585df3ddc7b475d39e72d"
    },
    {
      "bel": "p(HGNC:ITGB1)",
      "concept": {
        "name": "ITGB1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "ce18e44c941c45852f1a4a546a08b5fd"
    },
    {
      "bel": "p(HGNC:MBP)",
      "concept": {
        "name": "MBP",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "648e8365c587b532946d8a49fc81cb90"
    },
    {
      "bel": "p(HGNC:NFE2L2)",
      "concept": {
        "name": "NFE2L2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7e8941fff5d3be67079854e55d40d075"
    },
    {
      "bel": "p(HGNC:S1PR1)",
      "concept": {
        "name": "S1PR1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "790a4a883be37d698cd7f2676b3e0d49"
    },
    {
      "bel": "p(HGNC:TNF)",
      "concept": {
        "name": "TNF",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "fdc1c1f5a73c3c992b6eb71ce9b6908e"
    },
    {
      "bel": "p(HGNC:VCAM1)",
      "concept": {
        "name": "VCAM1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "1f8295903afe529c3261018587ec7a88"
    },
    {
      "bel": "p(HGNCGENEFAMILY:Interferons)",
      "concept": {
        "name": "Interferons",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Protein",
      "id": "72e3eb78f10f5c364525987ecfd4e7d7"
    },
    {
      "bel": "p(MESH:\"Antibodies, Monoclonal, Humanized\")",
      "concept": {
        "name": "Antibodies, Monoclonal, Humanized",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "4f138e70e00dacf78022467d392b7f23"
    },
    {
      "bel": "p(MESH:\"Interferon-gamma\")",
      "concept": {
        "name": "Interferon-gamma",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "871324133a65adcc8bb325550c3e9c24"
    },
    {
      "bel": "p(MESH:\"Matrix Metalloproteinases\")",
      "concept": {
        "name": "Matrix Metalloproteinases",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "77d4d52a4ce564d9659a3134fbd68e16"
    },
    {
      "bel": "p(MESH:\"Receptors, Very Late Antigen\")",
      "concept": {
        "name": "Receptors, Very Late Antigen",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "a7570504f6d8c6303eeeb4a8dc4f3257"
    },
    {
      "bel": "p(MESH:Enzymes)",
      "concept": {
        "name": "Enzymes",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "a4f1227d29fe2fc8121bd45717a7bb58"
    },
    {
      "bel": "path(DOID:\"atrioventricular block\")",
      "concept": {
        "name": "atrioventricular block",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "d05fb8a1a10bef4f7beb4d091349749a"
    },
    {
      "bel": "path(DOID:\"autoimmune disease of central nervous system\")",
      "concept": {
        "name": "autoimmune disease of central nervous system",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "8b5852517be33b11cc24e28bdc12ef19"
    },
    {
      "bel": "path(DOID:\"axonal neuropathy\")",
      "concept": {
        "name": "axonal neuropathy",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "586b835d2dd7f4d365386ebf14c115d6"
    },
    {
      "bel": "path(DOID:\"herpes simplex\")",
      "concept": {
        "name": "herpes simplex",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "554da6050638f453512e47448d0c7f51"
    },
    {
      "bel": "path(DOID:\"mental depression\")",
      "concept": {
        "name": "mental depression",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "444223db67421fa96923920d0a8fd533"
    },
    {
      "bel": "path(DOID:\"multiple sclerosis\")",
      "concept": {
        "name": "multiple sclerosis",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "828e65d53fe5c29b364f79cfd5304f90"
    },
    {
      "bel": "path(DOID:\"optic neuritis\")",
      "concept": {
        "name": "optic neuritis",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "791036b0fa3041ed717e835743f78526"
    },
    {
      "bel": "path(DOID:\"pain disorder\")",
      "concept": {
        "name": "pain disorder",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "58e84f7be103e5e8d5e8f2b4a0bd2369"
    },
    {
      "bel": "path(DOID:\"progressive multifocal leukoencephalopathy\")",
      "concept": {
        "name": "progressive multifocal leukoencephalopathy",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "4f9b944390c450df4675270bc58f3417"
    },
    {
      "bel": "path(DOID:\"relapsing-remitting multiple sclerosis\")",
      "concept": {
        "name": "relapsing-remitting multiple sclerosis",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "b21b34dd5c948d6330eceb5f4eb9649f"
    },
    {
      "bel": "path(DOID:\"secondary progressive multiple sclerosis\")",
      "concept": {
        "name": "secondary progressive multiple sclerosis",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "38f0567d9ceb0ade6bf93de56a897396"
    },
    {
      "bel": "path(DOID:\"thyroid gland disease\")",
      "concept": {
        "name": "thyroid gland disease",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "58e0f6fda08989c7b40fc7fb26a4ab1f"
    },
    {
      "bel": "path(DOID:diarrhea)",
      "concept": {
        "name": "diarrhea",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "5440dc6679d5147c19c34cae200a4588"
    },
    {
      "bel": "path(DOID:leukemia)",
      "concept": {
        "name": "leukemia",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "c6ceb29ebcaf0b525d3b287f5df34213"
    },
    {
      "bel": "path(DOID:leukopenia)",
      "concept": {
        "name": "leukopenia",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "9381509df60d11b175a24ec9523e03c0"
    },
    {
      "bel": "path(DOID:lymphopenia)",
      "concept": {
        "name": "lymphopenia",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "0df6de8d4400ab1d10f7952ea96128b4"
    },
    {
      "bel": "path(DOID:myelitis)",
      "concept": {
        "name": "myelitis",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "1452aeef9341de994a8094343ffd1b03"
    },
    {
      "bel": "path(DOID:tuberculosis)",
      "concept": {
        "name": "tuberculosis",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "6c996f45512cf6f67ba4f82ac5953c1a"
    },
    {
      "bel": "path(EFO:\"experimental autoimmune encephalomyelitis\")",
      "concept": {
        "name": "experimental autoimmune encephalomyelitis",
        "namespace": "EFO"
      },
      "function": "Pathology",
      "id": "32b1c17fbec51b6b7c44e27150d888c7"
    },
    {
      "bel": "path(HP:\"Abdominal pain\")",
      "concept": {
        "name": "Abdominal pain",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "368ee09b45af619a8e4d4bf202aa8799"
    },
    {
      "bel": "path(HP:\"Atrophy/Degeneration affecting the brainstem\")",
      "concept": {
        "name": "Atrophy/Degeneration affecting the brainstem",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "2551eb4c07fff93308825ceec99801ba"
    },
    {
      "bel": "path(HP:\"Axonal loss\")",
      "concept": {
        "name": "Axonal loss",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "ea3a3af52b70a2c9cf17028a2e14bb03"
    },
    {
      "bel": "path(HP:\"CNS demyelination\")",
      "concept": {
        "name": "CNS demyelination",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "fb7670f43e6511eda6fbd0b0517820a6"
    },
    {
      "bel": "path(HP:\"Chest tightness\")",
      "concept": {
        "name": "Chest tightness",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "8d5a5c3bb00cfa864b6b05f95eb31025"
    },
    {
      "bel": "path(HP:\"Disseminated viral infection\")",
      "concept": {
        "name": "Disseminated viral infection",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "29ae6b2b249dc65b2e6a38fadb4089a3"
    },
    {
      "bel": "path(HP:\"Gallbladder dysfunction\")",
      "concept": {
        "name": "Gallbladder dysfunction",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "7b53a3183f0b1b84ecb92d16f1eba4fe"
    },
    {
      "bel": "path(HP:\"Macular edema\")",
      "concept": {
        "name": "Macular edema",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "95e589ef10fce761a6488f688872529c"
    },
    {
      "bel": "path(HP:\"Rheumatoid arthritis\")",
      "concept": {
        "name": "Rheumatoid arthritis",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "98d447d34045bc13e3b0a9210f3a0e9b"
    },
    {
      "bel": "path(HP:Allergy)",
      "concept": {
        "name": "Allergy",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "efc11be1e0509394da6dcf12cbd2b514"
    },
    {
      "bel": "path(HP:Bradycardia)",
      "concept": {
        "name": "Bradycardia",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "553b0a498b1adffca12cd87ef87299e4"
    },
    {
      "bel": "path(HP:Dyspnea)",
      "concept": {
        "name": "Dyspnea",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "963560b5f8fac4a36096e31cb33a61ea"
    },
    {
      "bel": "path(HP:Fatigue)",
      "concept": {
        "name": "Fatigue",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "e398c9a963ab9c48ac72f9f35351cc80"
    },
    {
      "bel": "path(HP:Flushing)",
      "concept": {
        "name": "Flushing",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "f6ac1eb2869191a53cd71b7537802163"
    },
    {
      "bel": "path(HP:Headache)",
      "concept": {
        "name": "Headache",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "a24ae0bd1e3980c71af01ddc357c55ad"
    },
    {
      "bel": "path(HP:Lipoatrophy)",
      "concept": {
        "name": "Lipoatrophy",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "720272b57f418217f1821418a471ca47"
    },
    {
      "bel": "path(HP:Nausea)",
      "concept": {
        "name": "Nausea",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "114df52c060f80eaf29119388417d6f7"
    },
    {
      "bel": "path(HP:Palpitations)",
      "concept": {
        "name": "Palpitations",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "6e15b3eeafacc7f9bc481727eb25ada8"
    },
    {
      "bel": "path(HP:Spasticity)",
      "concept": {
        "name": "Spasticity",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "010066b8cb9d415451e34e48fedd5c4a"
    },
    {
      "bel": "path(MESH:\"Autoimmune Diseases\")",
      "concept": {
        "name": "Autoimmune Diseases",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "0aeb632260f15842cdd2b5e3c4b15c15"
    },
    {
      "bel": "path(MESH:\"Diffuse Axonal Injury\")",
      "concept": {
        "name": "Diffuse Axonal Injury",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "5c071ab33c311b21362da90fd43f77d1"
    },
    {
      "bel": "path(MESH:\"Epstein-Barr Virus Infections\")",
      "concept": {
        "name": "Epstein-Barr Virus Infections",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "152f451c5e17ac13db8d9a8224992412"
    },
    {
      "bel": "path(MESH:\"Injection Site Reaction\")",
      "concept": {
        "name": "Injection Site Reaction",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "045dcc5771f375a42a9157926ebbec02"
    },
    {
      "bel": "path(MESH:\"Vitamin D Deficiency\")",
      "concept": {
        "name": "Vitamin D Deficiency",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "850acfca9d6ca38eeed01904c836eeb7"
    },
    {
      "bel": "path(MESH:Alopecia)",
      "concept": {
        "name": "Alopecia",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "a3f6ab22b2c073151cd3721761fd2f8b"
    },
    {
      "bel": "path(MESH:Autoimmunity)",
      "concept": {
        "name": "Autoimmunity",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "2a0e48081887306f061cbcd497625105"
    },
    {
      "bel": "path(MESH:Cardiotoxicity)",
      "concept": {
        "name": "Cardiotoxicity",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "96d1d2b18719b6a56f5d6c708acc1104"
    },
    {
      "bel": "path(MESH:Infection)",
      "concept": {
        "name": "Infection",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "572a317d84677724217aff971083c770"
    },
    {
      "bel": "path(MESH:Inflammation)",
      "concept": {
        "name": "Inflammation",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "10cd96fd4056a5e6c27264e0130e89f9"
    },
    {
      "bel": "path(MESH:Smoking)",
      "concept": {
        "name": "Smoking",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "421977e25516b65692cc5c7ed794a7eb"
    }
  ]
}